<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003237.pub2" GROUP_ID="RENAL" ID="485801030216533417" MERGED_FROM="" MODIFIED="2014-07-22 16:16:57 +1000" MODIFIED_BY="Gail Y Higgins" REVIEW_NO="018" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-07-22 16:16:57 +1000" MODIFIED_BY="Gail Y Higgins">
<TITLE>Modes of administration of antibiotics for symptomatic severe urinary tract infections</TITLE>
<CONTACT>
<PERSON ID="C0BA9FC282E26AA201557EE87808F096" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annette</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pohl</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>annette.pohl@uniklinik-freiburg.de</EMAIL_1>
<EMAIL_2>anpohl@yahoo.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Center of Clincial Studies</DEPARTMENT>
<ORGANISATION>University Clinic Freiburg</ORGANISATION>
<ADDRESS_1>Elsässerstr. 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Freiburg</CITY>
<ZIP>79110</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-07-22 16:15:59 +1000" MODIFIED_BY="Gail Higgins">
<PERSON ID="C0BA9FC282E26AA201557EE87808F096" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annette</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pohl</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>annette.pohl@uniklinik-freiburg.de</EMAIL_1>
<EMAIL_2>anpohl@yahoo.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Center of Clincial Studies</DEPARTMENT>
<ORGANISATION>University Clinic Freiburg</ORGANISATION>
<ADDRESS_1>Elsässerstr. 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Freiburg</CITY>
<ZIP>79110</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-06-11 16:46:54 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="13" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="8" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-22 16:16:57 +1000" MODIFIED_BY="Gail Y Higgins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-07-22 16:16:57 +1000" MODIFIED_BY="Gail Y Higgins">
<DATE DAY="22" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Minor copy edit of 2 study names</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="11" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-11 15:30:52 +1000" MODIFIED_BY="Narelle S Willis"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<SUMMARY MODIFIED="2008-06-11 15:34:31 +1000" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2008-06-11 15:34:31 +1000" MODIFIED_BY="Narelle S Willis">No evidence that oral antibiotic therapy is less effective for treating urinary tract infection than intravenous antibiotics</TITLE>
<SUMMARY_BODY>
<P>Severe urinary tract infection (UTI) is a common infection in adults and children, causing acute disease with a variety of symptoms such as fever and flank pain. This may lead to kidney damage, kidney failure or hypertension. Standard therapy involves antibiotics given at least initially by injection. This review identified 15 studies (1743 participants). The results of this review suggest oral therapy is equally effective in treating UTI and preventing long-term damage. This might reduce costs but also inconvenience for the patient. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-11 17:17:57 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND>
<P>Urinary tract infection (UTI), worldwide, is a major source of disease in children and adults. As it may have long-term consequences such as kidney failure and hypertension, it is important to treat patients with UTI adequately. Although standard management of severe UTI usually means intravenous (IV) therapy, at least initially, there are studies showing that oral therapy may also be effective.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess whether the mode of administration of antibiotic therapy for severe UTI has an effect on cure rate, reinfection rate and kidney scarring.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-06-11 16:49:09 +1000" MODIFIED_BY="Narelle S Willis">
<P>The Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in <I>The Cochrane Library)</I>, MEDLINE and EMBASE were searched. No language restriction was applied. Reference lists of relevant articles and reviews were checked for additional studies and authors of relevant articles/abstracts were contacted for further information.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials (RCTs) comparing different modes of antibiotic application for patients with severe UTI (children and adults) were considered. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-11 17:17:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Study quality was assessed and data extracted. Statistical analyses were performed using the random effects model and the results expressed as risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous data with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifteen RCTs (1743 patients) were included. Studies compared oral versus parenteral treatment (1), oral versus switch treatment (initial intravenous (IV) or intramuscular (IM) therapy followed by oral therapy) (5), switch versus parenteral treatment (6) and single dose parenteral followed by oral therapy versus oral (1) or switch therapy (3). There was a variety of short-term and long-term outcomes, but no pooled outcomes showed significant differences. Most included studies were small though and there were few outcomes for combination in a meta-analysis. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is no evidence suggesting that oral antibiotic therapy is less effective for treatment of severe UTI than parenteral or initial parenteral therapy. The results of this review suggest that the mode of application does not determine therapeutic success. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<BACKGROUND MODIFIED="2008-06-11 15:36:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Urinary tract infection (UTI) is a major source of disease with an estimated 150 million patients/year worldwide, costing the global economy more than six billion US dollars (<LINK REF="REF-Gonzalez-1999" TYPE="REFERENCE">Gonzalez 1999</LINK>). It is a condition that causes substantial suffering for the patient and, especially if not treated properly, may - in extreme cases - cause substantial kidney scarring. It is thought that this might have long-term consequences such as progressive kidney failure and the development of hypertension (<LINK REF="REF-Ransley-1981" TYPE="REFERENCE">Ransley 1981</LINK>; <LINK REF="REF-Smellie-1994" TYPE="REFERENCE">Smellie 1994</LINK>). It is therefore important to diagnose early and treat patients with acute UTI adequately.</P>
<P>As many as 80% to 90% of symptomatic UTIs are caused by <I>Escherichia coli</I> (<LINK REF="REF-Winberg-1974" TYPE="REFERENCE">Winberg 1974</LINK>; <LINK REF="REF-Orenstein-1999" TYPE="REFERENCE">Orenstein 1999</LINK>). Infections can be classified into (1) infection involving the kidney parenchyma (acute pyelonephritis) and (2) infections limited to the lower urinary tract. Ten to 20% of the symptomatic infections cannot be classified, and for practical reasons all patients with severe, symptomatic UTI are best treated as having kidney infection (<LINK REF="REF-Hansson-1999" TYPE="REFERENCE">Hansson 1999</LINK>). Standard management of severe UTI recommends hospitalisation and therapy with intravenous (IV) antibiotics (<LINK REF="REF-Kunin-1994" TYPE="REFERENCE">Kunin 1994</LINK>; <LINK REF="REF-McCracken-1989" TYPE="REFERENCE">McCracken 1989</LINK>; <LINK REF="REF-Stamm-1993" TYPE="REFERENCE">Stamm 1993</LINK>). However, oral therapy or initial IV therapy followed by oral therapy after cessation of fever would reduce costs, if is was shown to be effective in treating the infection and preventing complications. There are studies showing that oral therapy might be as effective in treating severe UTI as parenteral therapy, whereas other authors state that only parenteral therapy is feasible. In a recent survey about management and treatment of children with suspected acute pyelonephritis, 30% of all responding Belgian paediatricians considered oral treatment, the others recommended IV therapy (<LINK REF="REF-Levtchenko-2001" TYPE="REFERENCE">Levtchenko 2001</LINK>). This heterogeneity in treatment strategies underlines the need for further assessment in regard to drug administration routes in patients with severe UTI.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this review was to assess whether the application mode of an antibiotic therapy applied for severe UTI has an effect on outcomes such as cure rate, reinfection rate and kidney scarring.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<SELECTION_CRITERIA MODIFIED="2008-06-11 15:37:28 +1000" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES>
<P>All randomised controlled trials (RCTs) that compared one of the specified types of intervention for treatment of symptomatic severe UTI were included. Where studies included patients with other infections (e.g. pneumonia, sepsis), studies were included if results for therapy of UTI could be extracted separately. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>The aim of this review was to analyse whether the application mode of antibiotic drugs has an effect on the outcome of severe UTI. One of the most problematic issues was to define severe UTI and thereby the participants to be included. Anatomically, UTIs can be classified into lower and upper UTI and whereas lower UTI can usually be treated with oral antibiotics, there is much controversy about therapy for upper UTI. There is no evident clinical distinction between the two entities. </P>
<P>For the purpose of this review, severe symptomatic UTI was defined as the clinical syndrome of fever, bacteriuria, pyuria and - beyond infancy - symptoms of UTI (flank pain, dysuria) and patients with severe symptomatic UTI, supposedly pyelonephritis, were included. Studies that included only patients with mild UTI (cystitis) were excluded. Complicated UTI was defined as UTI in patients with pre-existing complicating kidney disease such as obstruction, neurogenic bladder, chronic catheterisation.</P>
<P>Studies that included only patients with complicated UTI were excluded under the assumption that the underlying bacterial spectrum is different to that of uncomplicated severe UTI. Under the same assumption, studies that included only patients with nosocomially acquired UTI were also excluded. However, studies were not required to specifically exclude patients with urinary tract anomalies and studies that also included patients with complicated infections were included. Especially in paediatric studies, it was not obvious before infection whether a patient had a urinary tract anomaly and therefore if they had a complicated or uncomplicated UTI. There was no age or sex restriction.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-06-11 15:37:05 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Oral versus parenteral (defined as IV or intramuscular (IM)) antibiotic therapy for the total duration of the therapy.</LI>
<LI>Oral versus switch therapy, defined as initial parenteral treatment with subsequent oral antibiotic treatment.</LI>
<LI>Switch therapy versus parenteral therapy total duration of the therapy.</LI>
<LI>Single shot parenteral therapy (initial IM dose) followed by oral therapy versus oral therapy.</LI>
<LI>Single shot parenteral therapy (initial IM dose) followed by oral therapy versus switch therapy.</LI>
</OL>
<P>Studies comparing IM versus IV therapy (i.e. two parenteral treatment modes) were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-11 15:37:28 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI> Cure rates<I> </I>(defined as no clinical signs, bacteriological cure rate defined as eradication of bacteria, combined clinical and bacteriological cure rate defined as no clinical signs and eradication of bacteria): a) under therapy, b) at end of therapy, and c) after an interval.</LI>
<LI>Reinfection rate (defined as new pathogen in urine culture): a) at end of therapy, and b) after an interval (length of interval varied in the included studies).</LI>
<LI>Relapse rate (defined as initial pathogen in urine culture after it had been eradicated): a) at end of therapy, and b) after an interval (length of interval varied in the included studies).</LI>
<LI>Number of patients with fever after 48 hours.</LI>
<LI>Number of patients with kidney scarring (DMSA scan) after six months.</LI>
<LI>Adverse events.</LI>
<LI>Time to cessation of fever.</LI>
<LI>Time of clinical symptoms.</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-11 16:34:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Relevant studies were identified by searching electronic databases (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> <I>Electronic search strategies</I>) and other resources:</P>
<UL>
<LI>Cochrane Renal Group's specialised register.</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL in <I>The Cochrane Library</I>, Issue 2, 2007).</LI>
</UL>
<P>CENTRAL and the Cochrane Renal Group's specialised register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<LINK REF="REF-Master-List-2007" TYPE="REFERENCE">Master List 2007</LINK>). Please refer to The Cochrane Renal Review Group's Module in <I>The Cochrane Library</I> for the complete list of nephrology conference proceedings searched.</P>
<UL>
<LI>MEDLINE (from 1966 to June 2007): the search strategy incorporated the Cochrane highly sensitive search strategy for identifying RCTs in MEDLINE (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>).</LI>
<LI>EMBASE (from 1980 to June 2007): the search strategy incorporated a sensitive strategy for identifying RCTs in EMBASE (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>).</LI>
<LI>Reference lists of identified studies and major reviews.</LI>
<LI>Contact with researchers active in the field and primary authors of identified relevant studies for details of unpublished studies.</LI>
</UL>
<P>No language restrictions were applied. Letters, abstracts, and unpublished studies were accepted to reduce publication bias. If duplicate publication was suspected, authors were contacted for clarification, and if confirmed, the publication with the most and/or the longest follow-up data was used for the review.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>The search strategy as described above was performed by one author (AP) with the help of a librarian. Titles and abstracts were screened and if necessary, the full text was assessed. Studies reported in non-English language were translated before assessment. In case of unclear presentation or incomplete data, information was sought from the original author by written correspondence or in one case (<LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>) by telephone. From two studies (<LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>), only incomplete data was included. These studies are completed but not as yet published.</P>
<P>Data was extracted using standard data extraction sheets as provided by the Cochrane Renal Group. The quality of the studies was assessed without blinding to authorship. The items assessed were allocation concealment, blinding, drop out rate and use of intent-to-treat analysis. Allocation concealment was classified as "adequate" in case of a randomisation method that would not allow the investigator or the patient to know or influence to which intervention group the patient was enrolled before the actual begin of the study. If there was no further information about method of randomisation, it was classified as "unclear". There were no studies with openly inadequate allocation concealment. Blinding was divided into blinding of patients, clinicians and outcome assessors. Dropout rate lists the percentage of patients lost to follow-up or with no data for the primary outcome measure. In order to be classified as intention-to-treat analysis, study assessment had to confirm that all randomised patients were analysed according to randomisation schedule.</P>
<P>For statistical analysis dichotomous outcomes were expressed as risk ratio (RR) with a 95% confidence interval (CI). For continuous outcomes (time to cessation of fever and time of clinical symptoms), the mean difference (MD) was used, also with a 95% CI. In both cases, data were pooled using the random effects model, but the fixed effects model was also applied in order to control the robustness of the analysis. Heterogeneity was assessed using a Chi-square statistic with an alpha of 0.1 for statistical significance, and also the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
<P>There were insufficient studies to examine publication bias.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY_DESCRIPTION MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Over 2,000 titles and abstracts were identified and screened. Fifty reports were identified as potentially relevant and full text versions were obtained, 34 studies were subsequently excluded (for details see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>The remaining 15 studies (16 reports, 1743 participants) fulfilled the inclusion criteria and were included in this review. The authors of six studies were contacted for further information (<LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>), five authors replied (<LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>). For two studies (<LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>), only preliminary data was included, the studies have been completed but are as yet unpublished. Studies were conducted in eight countries (USA, France, Switzerland, Turkey, Iran, Italy, Spain and Thailand) and published in English, French, Italian and German. Studies were published between 1989 and 2007.</P>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Nine studies recruited children in different age groups (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>), among these, six studies including children less than one year of age (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>) and <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK> did not specify the lower age boundary. Of the remaining six studies, <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK> only included women and <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK> only included pregnant women.</P>
<P>The objective of this review was to compare different application modes of antibiotics in severe UTI, which means patients with pyelonephritis rather than cystitis. Clinically, it is not always easy to distinguish between these entities, especially in small children. Therefore, the definition of UTI varied in different studies. All studies required clinical signs and symptoms of UTI and a positive urinalysis. In all but two studies, a positive urine culture before treatment was a prerequisite. <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK> did not exclude patients with a negative urine culture (one each group) or without pretreatment culture (nine patients) if the clinical signs and symptoms were strongly indicative of pyelonephritis. In <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>, two patients in each group had received antibiotics 24 hours before collection of urine culture and, although their urine cultures were negative, they were included. Severity of UTI was defined differently. Most studies used fever as a sign of severity, other studies also required laboratory values (elevated CRP, leucocytosis) (<LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>) or specified that the clinical condition "had to require parenteral antibiotics" (<LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>). Symptoms of UTI and positive urinalysis were not always further defined and the method of urine collection was only described in seven studies (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>). In seven studies (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>), patients with known urologic anomalies were excluded, whereas in six studies, patients with complicated UTI were included (<LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>; <LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>; <LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>). Studies that only and explicitly included patients with complicated UTI were excluded from this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<UL>
<LI>Six studies analysed switch therapy (IV therapy initially followed by oral antibiotic therapy) versus parenteral (IV or IM) therapy in UTI (<LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>; <LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>; <LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>). The IV antibiotics used were cefotaxime, amoxicillin/clavulanic acid, ceftriaxone, ceftazidime, ciprofloxacin, netilmicin, amikacin and gentamicin. The oral antibiotics used were ciprofloxacin, amoxicillin/clavulanic acid, cefixime or ceftibuten. Duration in the two treatment groups was usually equivalent and varied between 4 to 14 days.</LI>
<LI>Five studies compared oral versus switch therapy (<LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>), using ceftibuten, cefixime, amoxicillin/clavulanic acid and ciprofloxacin as oral antibiotics and ceftriaxone, cefotaxime, ciprofloxacin and ceftizoxime as IV or IM therapy. One study (<LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>) did not specify duration of therapy, and all other studies treated between 10 and 14 days.</LI>
<LI>One study assessed oral versus parenteral therapy (<LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>) using norfloxacin as oral therapy for seven days and aztreonam as parenteral therapy.</LI>
<LI>Two studies used single shot parenteral therapy (IM or IV) followed by oral therapy versus switch therapy (<LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>). Antibiotics used were ceftriaxone and cefazolin as parenteral drugs and cephalexin and cefixime applied orally, treatment duration was 10 days.</LI>
<LI>One study compared single dose parenteral (IM) therapy followed by oral therapy versus oral therapy (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>) using ceftriaxone as IM and trimethoprim-sulfamethoxazole as oral agent for 10 days.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Outcomes varied in the different studies, so it was not always feasible to combine results. Even the primary outcome (cure rate) was defined differently. Cure rates were presented as clinical or bacteriological or combined clinical and bacteriological cure rates, outcome was assessed during therapy or at end of therapy or after an interval of several weeks. Only nine studies presented adverse events (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>).</P>
<P>Further study characteristics are presented in the table - <I>Characteristics of included studies</I>.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Only RCTs were included (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
<I> - Methodological quality of included studies</I>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>There were eight studies with adequate allocation concealment (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>) and seven studies with unclear (<LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>; <LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>; <LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>). No correlation between date of publication and allocation concealment could be revealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Blinding of patients would only have been feasible with a double dummy design and therefore none of the studies blinded patients. Only <LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK> concealed the mode of antibiotic application from the treating clinicians. In six studies, outcome assessors were blinded (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>). In the remaining studies, there was no information about blinding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat</HEADING>
<P>Only three studies analysed results on an intention-to-treat basis (<LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>) and it was unclear in four studies (<LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>; <LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>; <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dropout rates</HEADING>
<P>Six studies had a dropout rate of more than 10% (<LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>; <LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>; <LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>; <LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>; <LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Due to different outcome parameters, few studies were available for combination in a meta-analysis. The results were the same in a fixed effects model or a random effects model, therefore only the results of the random effects model are reported.</P>
<SUBSECTION>
<HEADING LEVEL="3">Switch versus parenteral therapy</HEADING>
<P>Six studies (373 patients) compared switch versus parenteral therapy. In all outcomes there was no significant difference between switch and parenteral therapy.<BR/>
</P>
<UL>
<LI>The number of patients with fever after 48 hours was not significantly different between the two groups (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (1 study, 20 patients): RR 5.00, 95% CI 0.27 to 92.62).</LI>
<LI>Under therapy, there was no significantly difference in bacterial eradication (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (1 study, 19 patients): RR 0.79, 95% CI 0.54 to 1.15).</LI>
<LI>At the end of therapy, there was no statistical difference in clinical cure (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (2 studies, 137 patients): RR 1.01, 95% CI 0.94 to 1.10, I² = 0%) or bacteriological cure (i.e. bacterial eradication) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (2 studies, 76 patients): RR 1.11, 95% CI 0.90 to 1.36, I² not applicable). The combined outcome, clinical and bacteriological cure at the end of therapy, was also not significantly different (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (4 studies, 294 patients): RR 0.99, 95% CI 0.94 to 1.04, I² = 4.3%).</LI>
<LI>At the end of therapy (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) and after an interval (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), the rate of reinfection was not statistically different (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (1 study, 72 patients): RR 1.00, 95% CI 0.15 to 6.72; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (4 studies, 239 patients): RR 0.76, 95% CI 0.30 to 1.90, I² = 0%).</LI>
<LI>The number of patients with clinical and bacteriological cure after an interval was not statistically different. There was some heterogeneity (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (3 studies, 219 patients): RR 0.99, 95% CI 0.89 to 1.11, I² = 39.0%). Subgroup analysis showed that for the paediatric studies clinical and bacteriological cure was (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>
<U>
<I>.</I>1</U> (2 studies, 138 patients): RR 1.03, 95% CI 0.96 to 1.10, I² =5.9%) and for the adult study (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>
<U>.2</U> (1 study, 81 patients): RR 0.92, 95% CI 0.73 to 1.16). Age was not the only distinguishing factor between the paediatric studies and the adult study. In the paediatric studies, the outcome was assessed 10 to 20 days (<LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>) or 14 days after stopping therapy (<LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>) compared to 10 to 84 days in the adult study (<LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>).</LI>
<LI>The relapse rate was not significantly different (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> (3 studies, 203 patients): RR 2.79, 95% CI 0.30 to 25.67, I² not applicable).</LI>
<LI>Kidney scarring on DMSA scan after six months did not differ significantly (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (1 study, 36 patients): RR 0.92, 95% CI 0.56 to 1.50).</LI>
<LI>The number of patients with adverse events was statistically the same (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (4 studies, 292 patients): RR 0.85, 95% CI 0.19 to 3.83, I² = 44.8%). There were only minor side effects, mainly gastrointestinal upsets. There was moderate heterogeneity. Subgroup analysis showed that this heterogeneity might be explained by age. The paediatric studies had a RR of 0.67 (95% CI 0.30 to 1.53, I² = 0%) and the adult study had an RR of 0.85 (95% CI 0.19 to 3.83).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Switch versus oral therapy</HEADING>
<P>Five studies (1040 patients) compared switch therapy with oral therapy. Two of these studies were included with preliminary data only (<LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>), they are both still awaiting publication. There was no significant difference between switch and oral therapy for all outcomes.<BR/>
</P>
<UL>
<LI>Under therapy (A<I>nalysis 2.1</I>), at the end of therapy (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and after an interval (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), the number of patients with clinical and bacteriological cure was not statistically different (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (3 studies, 599 patients): RR 1.04, 95% CI 0.97 to 1.12, I² not applicable;<I> </I>
<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (1 study, 54 patients): RR 0.94, 95% CI 0.78 to 1.13; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> (3 studies, 493 patients): RR 0.97, 95% CI 0.93 to 1.01, I² = 0%).</LI>
<LI>The rate of reinfection at the end of therapy (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) and after an interval (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
<U>.1</U>, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
<U>.2</U>) did not differ statistically (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (1 study, 54 patients): RR 1.16, 95% CI 0.18 to 7.64; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
<U>.1</U> (symptomatic reinfection, 1 study, 187 patients): RR 0.67, 95% CI 0.27 to 1.67; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
<U>.2</U> (symptomatic and asymptomatic reinfection, 2 studies, 341 patients): RR 0.64, 95% CI 0.29 to 1.42, I² = 0%).</LI>
<LI>There was no significant difference in the number of patients with relapse at the end of therapy (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) or after an interval (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (1 study, 54 patients): RR 0.23, 95% CI 0.01 to 4.59; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> (1 study, 54 patients): RR 5.77, 95% CI 0.29 to 114.79).</LI>
<LI>Kidney scarring on DMSA scan after six months did not differ significantly (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> (2 studies, 424 patients): RR 0.87, 95% CI 0.35 to 2.16, I² = 77.8%). There was substantial heterogeneity among the two combined studies. In <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK> only 152/365 of the initially randomised patients contribute to the outcome. There is no final adjusted analysis available and therefore the preliminary data might be confounded. According to the author, there was no significant difference between treatment groups after adjustment for size of the initial kidney lesion. The DMSA scan results for <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK> are not available yet, but preliminary data showed that of the 90 scans available at the 1 year follow-up, 29% had scars with an equal proportion in the two treatment arms.</LI>
<LI>Mean time to cessation of fever did not differ significantly (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK> (3 studies, 834 patients): MD 0.40, 95% CI -2.94 to 3.74, I² = 17.4%).</LI>
<LI>The adverse events rate was not different between the two groups (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK> (2 studies, 506 patients): RR 0.96, 95% CI 0.06 to 15.02, I² not applicable).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus parenteral therapy</HEADING>
<P>One study (<LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>) compared oral versus parenteral therapy using norfloxacin as oral therapy. Patients with cystitis and pyelonephritis were included in the study, but only the latter were included in this review. Parenteral therapy had a significantly better outcome than oral therapy in both outcomes. For patients with cystitis, no difference could be detected with high cure rates in both groups.<BR/>
</P>
<UL>
<LI>The number of patients with bacteriological cure at the end of therapy was significantly higher in the parenteral group compared to the oral group (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (1 study, 38 patients): RR 1.37, 95% CI 1.02 to 1.84). This became even more evident after an interval (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (1 study, 38 patients): RR 1.95, 95% CI 1.24 to 3.08).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Switch versus single shot therapy</HEADING>
<P>Two studies (<LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>; <LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>) compared switch versus single shot therapy. Only two outcomes (number of patients with clinical cure under therapy and number of patients with adverse events) could be combined. There was no significant difference between both modes of application.<BR/>
</P>
<UL>
<LI>The number of patients with clinical cure under therapy was not significantly different (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (2 studies, 225 patients): RR 0.93, 95% CI 0.86 to 1.02, I² = 30.8%). At the end of therapy, all patients were clinically cured.</LI>
<LI>All patients showed bacterial eradication under therapy. At the end of therapy, there was no statistical difference in bacterial eradication (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK> (1 study, 110 patients): RR 0.96, 95% CI 0.79 to 1.16).</LI>
<LI>The mean time to cessation of fever (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) and mean duration of clinical symptoms (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>) were not significantly different (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> (1 study, 105 patients): MD 0.10, 95% CI -0.19 to 0.39; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK> (1 study, 105 patients): MD 0.30, 95% CI -0.16 to 0.76).</LI>
<LI>The adverse events rate was not statistically different (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK> (2 studies, 225 patients): RR 4.00, 95% CI 0.46-34.75, I² not applicable).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Single shot versus oral therapy</HEADING>
<P>One study (<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>) compared single shot IM followed by oral therapy versus oral therapy. All outcomes showed no significant difference between the two groups.<BR/>
</P>
<UL>
<LI>There was no statistical difference in the number of patients with clinical and bacteriological cure under therapy (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> (1 study, 69 patients): RR 0.97, 95% CI 0.81 to 1.17).</LI>
<LI>The number of patients with bacteriological cure under therapy was not statistically different (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (1 study, 69 patients): RR 0.97, 95% CI 0.83 to 1.14).</LI>
<LI>There was no patient with a reinfection after an interval in either group.</LI>
<LI>The adverse events rate was not statistically different (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK> (1 study, 69 patients): RR 1.37, 95% CI 0.33 to 5.68).</LI>
</UL>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Although severe UTI is usually treated exclusively with IV antibiotics (or at least initially) followed by oral antibiotics, this review suggests that the mode of application is not essential for the success of therapy. All comparisons of different application modes did not show a significant difference in the various outcomes analysed. The available oral antibiotics (especially third generation cephalosporins) seem to be potent enough to treat patients with pyelonephritis efficiently. Even long term outcomes such as kidney scarring do not seem to differ.</P>
<P>There is however insufficient evidence comparing oral versus parenteral therapy. Only one study was found, and only part of the data could be used as the study also included patients with mild/lower UTI (<LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>). This study found that oral therapy with norfloxacin was significantly less successful than parenteral therapy. According to this study, norfloxacin cannot be recommended as therapy for severe upper UTI. Ciprofloxacin, another fluoroquinolone, showed the same results when comparing oral and switch therapy.</P>
<P>When comparing switch and parenteral therapy, there was some heterogeneity in 1/11 outcomes (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The interpretation of this heterogeneity was difficult because in there was only often only one or two studies for each meta-analysis. Nevertheless, subgroup analysis showed either age or timing of outcome assessment (2 weeks versus up to 84 days) could explain this heterogeneity.</P>
<P>There was also substantial heterogeneity in the comparison of switch versus oral therapy involving two studies. <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK> included only preliminary data, there is as yet no final adjusted analysis available and therefore the preliminary data might be confounded. According to the author, there was no significant difference between treatment groups after adjustment for size of the initial kidney lesion. The DMSA scan results from <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK> are not available as yet, but preliminary data showed that of the 90 scans available at the 1 year follow-up, 29% had scars with an equal proportion in the two treatment arms. Therefore, at this point there is no conclusive evidence showing whether switch or oral therapy are equally effective or one is superior to the other.</P>
<P>Most included studies were of small sample size, many were of suboptimal quality. Studies were not designed as equivalence studies but rather they aimed to determine whether there were differences between two treatments. Failure to show a difference in an RCT does not necessarily mean that two treatments are equivalent (<LINK REF="REF-Jones-1996" TYPE="REFERENCE">Jones 1996</LINK>). There were few outcomes that could be combined in a meta-analysis and as previously stated some evidence is still awaiting publication (<LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>; <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>). Cure rates were high and, when reported, adverse events were uncommon, so that the fact that no statistical difference was found might not hold true for larger populations.</P>
<P>There was no evidence available concerning long-term outcomes other than kidney scarring. Information on long-term outcomes that are clinically more relevant is missing in all studies.</P>
<P>As long as there is no evidence suggesting that oral therapy is inferior to parenteral therapy or partially parenteral therapy, oral therapy might be used for treating patients with UTI. This would reduce the inconvenience of parenteral application especially in children. It might also help to reduce costs (and again inconvenience) by shortening the number of hospital days. Nevertheless, if treating with oral antibiotics, patients have to be supervised carefully to guarantee a good compliance and also to identify patients not tolerating oral drugs. In most studies, only patients tolerating oral therapy were included, and for children with pyelonephritis oral intake is often not possible in the beginning due to gastrointestinal upsets. Therefore, compliance and tolerance could impact greatly on efficacy and effectiveness. In addition, some oral antibiotics, such as third generation cephalosporins, are usually more expensive than many IV drugs. Therefore a proper cost-effectiveness analysis still has done to show that reduced days of hospitalisation outweighs drug costs.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<IMPLICATIONS_PRACTICE>
<P>This review has not shown that any mode of application of antibiotic therapy in severe UTI is superior to another. All included studies were small and not designed as equivalence studies. As long as there is no evidence suggesting that oral therapy is inferior to parenteral therapy, it might be justified to treat patients orally, at least in patients tolerating the oral pathway, because of less inconvenience for the patient and eventually less cost. When choosing oral antibiotics, third generation cephalosporins should be preferred, whereas there is weak evidence that norfloxacin should not be used when treating severe UTI.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<P>For the evaluation of long-term outcomes such as kidney scarring on DMSA scans, more studies are needed and the complete publication of the studies by <LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK> and <LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK> are awaited.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thank you to Mrs Edith Motschall for her assistance with the search strategy, Dr Gerd Antes and Prof Johannes Forster for their advice during the preparation of the protocol, and Drs Suzanne Geerlings, Vladimir Rafalsky and Thomas Welch for their editorial advice during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-06-11 16:29:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>AP - protocol development, literature search, data abstraction, data entry, data analysis, writing of review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDIES MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<INCLUDED_STUDIES MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-2001" NAME="Baker 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Baker PC. Nelson DS. Schunk JE. The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Archives of Pediatrics &amp;amp; Adolescent Medicine. 155(2):135-9, 2001 Feb. UI: 11177086&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker PC, Nelson DS, Schunk JE</AU>
<TI>The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>2</NO>
<PG>135-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11177086"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Childs-1990" NAME="Childs 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Childs SJ. Intravenous and oral ciprofloxacin versus intravenous ceftazidime for the treatment of severe urinary tract infections. [Comparative Study. Journal Article. Research Support, Non-U.S. Gov't] Diagnostic Microbiology &amp;amp; Infectious Disease. 13(2):161-3, 1990 Mar-Apr. UI: 2196152&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Childs SJ</AU>
<TI>Intravenous and oral ciprofloxacin versus intravenous ceftazidime for the treatment of severe urinary tract infections</TI>
<SO>Diagnostic Microbiology &amp; Infectious Disease</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>2</NO>
<PG>161-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2196152"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischbach-1989" NAME="Fischbach 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Fischbach M. Simeoni U. Mengus L. Jehl F. Monteil H. Geisert J. Janin A. Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Journal of Antimicrobial Chemotherapy. 24 Suppl B:177-83, 1989 Nov. UI: 2691478&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischbach M, Simeoni U, Mengus L, Jehl F, Monteil H, Geisert J et al</AU>
<TI>Urinary tract infections with tissue penetration in children: cefotaxime compared with amoxycillin/clavulanate</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1989</YR>
<VL>24 Suppl B</VL>
<PG>177-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2691478"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francois-1997" MODIFIED="2008-06-11 16:36:08 +1000" MODIFIED_BY="Narelle S Willis" NAME="Francois 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-11 16:36:08 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Francois P. Bensman A. Begue P. Artaz M-A. Coudeville L. Lebrun T. Scheimberg A. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: Oral cefixime or parenteral ceftriaxone after an initial IV combination therapy. [Journal: Conference Paper] Medecine et Maladies Infectieuses. Vol. 27(SPEC. ISS. JUNE)(pp 667-673), 1997. AN: 1997230388&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:36:08 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francois P, Bensman A, Begue P, Artaz MA, Coudeville L, Lebrun T et al</AU>
<TI>Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: Oral cefixime or parenteral ceftriaxone after an initial IV combination therapy</TI>
<SO>Medecine et Maladies Infectieuses</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>Spec. Iss. June</NO>
<PG>667-73</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:36:08 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:36:08 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1997230388"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gok-2001" NAME="Gok 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Gok F. Duzova A. Baskin E. Ozen S. Besbas N. Bakkaloglu A. Comparative study of cefixime alone versus intramuscular ceftizoxime followed by cefixime in the treatment of urinary tract infections in children. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Journal of Chemotherapy. 13(3):277-80, 2001 Jun. UI: 11450886&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gok F, Duzova A, Baskin E, Ozen S, Besbas N, Bakkaloglu A</AU>
<TI>Comparative study of cefixime alone versus intramuscular ceftizoxime followed by cefixime in the treatment of urinary tract infections in children</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>277-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11450886"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hoberman-1999" NAME="Hoberman 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Hoberman A. Wald ER. Hickey RW. Baskin M. Charron M. Majd M. Kearney DH. Reynolds EA. Ruley J. Janosky JE. Oral versus initial intravenous therapy for urinary tract infections in young febrile children.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] Pediatrics. 104(1 Pt 1):79-86, 1999 Jul. UI: 10390264&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M et al</AU>
<TI>Oral versus initial intravenous therapy for urinary tract infections in young febrile children</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>1 Pt 1</NO>
<PG>79-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10390264"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-1995" NAME="Millar 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Millar LK. Wing DA. Paul RH. Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial.[see comment]. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Obstetrics &amp;amp; Gynecology. 86(4 Pt 1):560-4, 1995 Oct. UI: 7675380&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar LK, Wing DA, Paul RH, Grimes DA</AU>
<TI>Outpatient treatment of pyelonephritis in pregnancy: A randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1995</YR>
<VL>86</VL>
<NO>4 Pt 1</NO>
<PG>560-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7675380"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mombelli-1999" NAME="Mombelli 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Mombelli G. Pezzoli R. Pinoja-Lutz G. Monotti R. Marone C. Franciolli M. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. [Clinical Trial. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial] Archives of Internal Medicine. 159(1):53-8, 1999 Jan 11. UI: 9892331&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M</AU>
<TI>Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: A prospective randomized clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9892331"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montini-2007" MODIFIED="2014-07-22 16:16:33 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Montini 2007" YEAR="2003">
<REFERENCE MODIFIED="2008-06-11 16:36:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montini G, Murer L, Gobber D, Comacchio S, Toffolo A, Dall'Amico R et al</AU>
<TI>Oral vs inital intravenous antibiotic treatment of urinary tract infections in children: a multicentre study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>816</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:36:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:36:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00446817"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-07-22 16:16:33 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-07-22 16:16:33 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00161330"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neuhaus-2008" MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Neuhaus 2008" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buechner K, Girardin F, Berger C, Willi U, Nadaf D, Neuhaus T for the Swiss Pyelonephritis Study Group</AU>
<TI>Randomised controlled trial of oral versus sequential intravenous/oral cephalosporins in DMSA scintigraphy-documented acute pyelonephritis [abstract no: COD. OP 18]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1511</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Abstract at the 38th conference meeting &amp;quot;Arbeitsgemeinschaft f&amp;#252;r P&amp;#228;diatrische Nephrologie&amp;quot; also presented at ESPN Meeting 2006, Abstract in Pediatric Nephrology, Vol. 21, page 1511, COPD.OP 18&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neuhaus TJ, Büchner K, Girardin E, Willi U, Berger C, Nadal D</AU>
<TI>Oral verus sequentiel intravenous/oral cephalosporin-therapy in DMSA-scintigraphy documented acute pyelonephritis: randomized Swiss pyelonephritis-study [abstract]</TI>
<TO>Orale versus sequentiell intravenös/orale Cephalosporin-Therapie bei DMSA-Szintigraphie dokumentierter akuter Pyelonephritis: Randomisierte Schweizer Pyelonephritis-Studie</TO>
<SO>Nieren- und Hochdruckkrankheiten</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>2</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Noorbakhsh-2004" NAME="Noorbakhsh 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Noorbakhsh S. Lari AR. Masjedian F. Mostafavi H. Alaghehbandan R. Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Saudi Medical Journal. 25(10):1513-5, 2004 Oct. UI: 15494842&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noorbakhsh S, Lari AR, Masjedian F, Mostafavi H, Alaghehbandan R</AU>
<TI>Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections</TI>
<SO>Saudi Medical Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1513-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15494842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puppo-1989" NAME="Puppo 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Puppo P. Germinale F. De Rose AF. [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. [Italian] [Clinical Trial. Comparative Study. English Abstract. Journal Article. Randomized Controlled Trial] Clinica Terapeutica. 129(2):113-21, 1989 Apr 30. UI: 2525996&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puppo P, Germinale F, De Rose A</AU>
<TI>Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients</TI>
<SO>Clinica Terapeutica</SO>
<YR>1989</YR>
<VL>129</VL>
<NO>2</NO>
<PG>113-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2525996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regnier-1989" MODIFIED="2008-06-11 16:36:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Regnier 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-11 16:36:54 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Regnier B. Brion N. Calamy G. Dureux JB. Humbert G. Imbert Y. Laffay J. Lucht F. Portier H. Rogez JP. Storck D. Christmann D. Tremolieres F. Veyssier P. Vinceneux P. Weinbreck P. A comparative study of intra-venous ceftriaxone followed by oral cefixime versus parenteral ceftriaxone alone in the treatment of severe upper urinary tract infections. [Journal] Presse Medicale. Vol. 18(32)(pp 1617-1621), 1989. AN: 1989252114&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:36:54 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Regnier B, Brion N, Calamy G, Dureux JB, Humbert G, Imbert Y et al</AU>
<TI>A comparative study of intra-venous ceftriaxone followed by oral cefixime versus parenteral ceftriaxone alone in the treatment of severe upper urinary tract infections</TI>
<SO>Presse Medicale</SO>
<YR>1989</YR>
<VL>18</VL>
<NO>32</NO>
<PG>1617-21</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:36:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:36:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1989252114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2002" NAME="Sanchez 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Sanchez M. Collvinent B. Miro O. Horcajada JP. Moreno A. Marco F. Mensa J. Milla J. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. [Clinical Trial. Journal Article. Randomized Controlled Trial] Emergency Medicine Journal. 19(1):19-22, 2002 Jan. UI: 11777865&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez M, Collvinent B, Miro O, Horcajada JP, Moreno A, Marco F et al</AU>
<TI>Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>1</NO>
<PG>19-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11777865"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilaichone-2001" NAME="Vilaichone 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Vilaichone A. Watana D. Chaiwatanarat T. Oral ceftibuten switch therapy for acute pyelonephritis in children. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Journal of the Medical Association of Thailand. 84 Suppl 1:S61-7, 2001 Jun. UI: 11529382&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilaichone A, Watana D, Chaiwatanarat T</AU>
<TI>Oral ceftibuten switch therapy for acute pyelonephritis in children</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84 Suppl 1</VL>
<PG>S61-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11529382"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-11 16:39:36 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Abraham-1982" MODIFIED="2008-06-11 16:37:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Abraham 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-11 16:37:11 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Abraham E. Baraff LJ. Oral versus parenteral therapy of pyelonephritis. [Journal] Current Therapeutic Research, Clinical &amp;amp; Experimental. Vol. 31(4)(pp 536-542), 1982. AN: 1982138442&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:37:11 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abraham E, Baraff LJ</AU>
<TI>Oral versus parenteral therapy of pyelonephritis</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1982</YR>
<VL>31</VL>
<NO>4</NO>
<PG>536-43</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:37:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:37:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1982138442"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmetagic-2003" NAME="Ahmetagic 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmetagic S, Jusufovic E, Cengic D, Koluder N, Bajramovic N, Calkic L et al</AU>
<TI>Clinical study of the efficacy of the antimicrobiotic agent amoxicillin + clavunalic acid (xiclav) and the possibility of early parenteral to oral switch therapy in the management of Infections</TI>
<SO>Medicinski Arhiv</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>5-6</NO>
<PG>263-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angel-1990" NAME="Angel 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Angel JL. O'Brien WF. Finan MA. Morales WJ. Lake M. Knuppel RA. Acute pyelonephritis in pregnancy: a prospective study of oral versus intravenous antibiotic therapy.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Obstetrics &amp;amp; Gynecology. 76(1):28-32, 1990 Jul. UI: 2193265&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angel JL, O'Brien WF, Finan MA, Morales WJ, Lake M, Knuppel RA</AU>
<TI>Acute pyelonephritis in pregnancy: a prospective study of oral versus intravenous antibiotic therapy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1990</YR>
<VL>76</VL>
<NO>1</NO>
<PG>28-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2193265"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benador-2001" NAME="Benador 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Benador D. Neuhaus TJ. Papazyan JP. Willi UV. Engel-Bicik I. Nadal D. Slosman D. Mermillod B. Girardin E. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. [Clinical Trial. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial] Archives of Disease in Childhood. 84(3):241-6, 2001 Mar. UI: 11207174&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benador D, Neuhaus TJ, Papazyan JP, Willi UV, Engel-Bicik I, Nadal D et al</AU>
<TI>Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>3</NO>
<PG>241-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11207174"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchi-1988" NAME="Buchi 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Buchi W. Casey PA. Experience with parenteral and sequential parenteral-oral amoxicillin/clavulanate (augmentin) in hospitalized patients. [Journal Article. Research Support, Non-U.S. Gov't] Infection. 16(5):306-12, 1988 Sep-Oct. &lt;br&gt;UI: 3215694&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchi W, Casey PA</AU>
<TI>Experience with parenteral and sequential parenteral-oral amoxicillin/clavulanate (augmentin) in hospitalized patients</TI>
<SO>Infection</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>5</NO>
<PG>306-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3215694"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunnag-2003" NAME="Bunnag 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Bunnag T. Kietkajornkul C. Out-patient antibiotics switch therapy in pediatric urinary tract infection. [Comparative Study. Journal Article] Journal of the Medical Association of Thailand. 86 Suppl 3:S543-8, 2003 Aug. &lt;br&gt;UI: 14700146&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag T, Kietkajornkul C</AU>
<TI>Out-patient antibiotics switch therapy in pediatric urinary tract infection</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2003</YR>
<VL>86 Suppl 3</VL>
<PG>543-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14700146"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cherubin-1986" NAME="Cherubin 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Cherubin C. Stilwell S. Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Scandinavian Journal of Infectious Diseases Supplement. 48:32-7, 1986. UI: 3535053&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cherubin C, Stilwell S</AU>
<TI>Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms</TI>
<SO>Scandinavian Journal of Infectious Diseases Supplement</SO>
<YR>1986</YR>
<VL>48</VL>
<PG>32-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3535053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Concia-2006" NAME="Concia 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Concia E. Marchetti F. LEVT07 Study Group. Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy. [Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Archivio Italiano di Urologia, Andrologia. 78(3):112-4, 2006 Sep. UI: 17137026&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Concia E, Marchetti F, LEVT07 Study Group</AU>
<TI>Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>2006</YR>
<VL>78</VL>
<NO>3</NO>
<PG>112-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17137026"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1987" NAME="Cox 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Cox CE. McCabe RE. Grad C. Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] American Journal of Medicine. 82(6B):59-64, 1987 Jun 26. UI: 3300312&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox CE, McCabe RE, Grad C</AU>
<TI>Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>82</VL>
<NO>6B</NO>
<PG>59-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3300312"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Scheife RT. Cox CE. McCabe RE. Grad C. Norfloxacin vs best parenteral therapy in treatment of moderate to serious, multiply-resistant, nosocomial urinary tract infections: a pharmacoeconomic analysis. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Urology. 32(3 Suppl):24-30, 1988 Sep. UI: 3138806&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheife RT, Cox CE, McCabe RE, Grad C</AU>
<TI>Norfloxacin vs best parenteral therapy in treatment of moderate to serious, multiply-resistant, nosocomial urinary tract infections: a pharmacoeconomic analysis</TI>
<SO>Urology</SO>
<YR>1988</YR>
<VL>32</VL>
<NO>3 Suppl</NO>
<PG>24-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3138806"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1989" MODIFIED="2008-06-11 16:37:34 +1000" MODIFIED_BY="Narelle S Willis" NAME="Cox 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-11 16:37:34 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Cox CE. Brief report: Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. [Journal: Conference Paper] American Journal of Medicine. Vol. 87(5 A)(pp 157S-159S), 1989. AN: 1990005329&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:37:34 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox CE</AU>
<TI>Brief report: Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>157S-159S</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:37:34 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:37:34 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990005329"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daly-1989" MODIFIED="2008-06-11 16:37:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Daly 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-11 16:37:45 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Daly JS. Worthington MG. Razvi SA. Robillard R. Brief report: Intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections. [Journal: Conference Paper] American Journal of Medicine. Vol. 87(5 A)(pp 232S-234S), 1989. AN: 1990005347&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:37:45 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daly JS, Worthington MG, Razvi SA, Robillard R</AU>
<TI>Brief report: Intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>232S-234S</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:37:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:37:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990005347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esposito-1991" NAME="Esposito 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Esposito S. Sardaro C. Gaeta GB. Galante D. Giusti G. Basani F. Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Journal of Chemotherapy. 3(1):42-4, 1991 Feb. UI: 2019862&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esposito S, Sardaro C, Gaeta GB, Galante D, Giusti G, Basani F</AU>
<TI>Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1991</YR>
<VL>31</VL>
<NO>1</NO>
<PG>42-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2019862"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-1991" NAME="Fang 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Fang GD. Brennen C. Wagener M. Swanson D. Hilf M. Zadecky L. DeVine J. Yu VL. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Antimicrobial Agents &amp;amp; Chemotherapy. 35(9):1849-55, 1991 Sep. &lt;br&gt;UI: 1952856&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang G, Brennen C, Wagener M, Swanson D, Hilf M, Zadecky L et al</AU>
<TI>Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: Prospective, randomized clinical and pharmacokinetic study</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1849-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1952856"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fass-1989" NAME="Fass 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Fass RJ. Plouffe JF. Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] American Journal of Medicine. 87(5A):164S-168S, 1989 Nov 30. UI: 2589361&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fass RJ, Plouffe JF, Russell JA</AU>
<TI>Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>164S-168S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2589361"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gangji-1989" MODIFIED="2008-06-11 16:37:59 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gangji 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-11 16:37:59 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Gangji D. Jacobs F. De Jonckheer J. Coppens L. Serruys E. Hanotte F. Motte S. Thys J-P. Brief report: Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia. [Journal: Conference Paper] American Journal of Medicine. Vol. 87(5 A)(pp 206S-208S), 1989. AN: 1990005341&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:37:59 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gangji D, Jacobs F, De Jonckheer J, Coppens L, Serruys E, Hanotte F et al</AU>
<TI>Brief report: Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>206S-208S</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:37:59 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:37:59 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990005341"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaut-1989" NAME="Gaut 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Gaut PL. Carron WC. Ching WT. Meyer RD. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] American Journal of Medicine. 87(5A):169S-175S, 1989 Nov 30. UI: 2686417&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaut PL, Carbon WC, Ching WTW, Meyer RD</AU>
<TI>Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>78</VL>
<NO>5A</NO>
<PG>169S-175S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2686417"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelfand-1993" NAME="Gelfand 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Gelfand MS. Simmons BP. Craft RB. Grogan J. Amarshi N. A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection. [Journal Article] American Journal of Medicine. 94(3A):126S-130S, 1993 Mar 22. UI: 8452168&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelfand MS, Simmons BP, Craft RB, Grogan J</AU>
<TI>A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94</VL>
<NO>3A</NO>
<PG>126S-130S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8452168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giamarellou-1989" NAME="Giamarellou 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Giamarellou H. Perdikaris G. Galanakis N. Davoulos G. Mandragos K. Sfikakis P. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Antimicrobial Agents &amp;amp; Chemotherapy. 33(8):1362-7, 1989 Aug. UI: 2679374&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P</AU>
<TI>Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>8</NO>
<PG>1362-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2679374"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harding-1993" MODIFIED="2008-06-11 16:38:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Harding 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-11 16:38:13 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Harding G. Nicolle L. Wenman W. Richards G. Louie T. Martel A. Simor A. Salit I. Gribble M. Randomised comparison of oral ciprofloxacin vs standard parenteral therapy in the treatment of complicated urinary tract infections. [Journal: Conference Paper] Drugs. Vol. 46(SUPPL. 3)(pp 333-334), 1993. AN: 1993243049&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:38:13 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harding G, Nicolle L, Wenman W, Richards G, Louie T, Martel A et al</AU>
<TI>Randomised comparison of oral ciprofloxacin vs standard parenteral therapy in the treatment of complicated urinary tract infections</TI>
<SO>Drugs</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>Suppl 3</NO>
<PG>333-4</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:38:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:38:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1993243049"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalager-1992" NAME="Kalager 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kalager T. Andersen BM. Bergan T. Brubakk O. Bruun JN. Doskeland B. Hellum KB. Hopen G. von der Lippe E. Rahm V. et al. Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety.[erratum appears in Scand J Infect Dis 1993;25(2):271]. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Scandinavian Journal of Infectious Diseases. 24(5):637-46, 1992. UI: 1465583&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalager T, Andersen BM, Bergan T, Brubakk O, Bruun JN, Doskeland B et al</AU>
<TI>Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: A prospective, randomized and controlled study of efficacy and safety. [erratum appears in Scand J Infect Dis 1993;25(2):271]</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1993</YR>
<VL>24</VL>
<NO>5</NO>
<PG>637-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1465583"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanellakopoulou-1990" MODIFIED="2008-06-11 16:38:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kanellakopoulou 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-06-11 16:38:28 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Kanellakopoulou K. Giamarellou H. Clinical experinece with parenteral and oral ofloxacin in severe infections. [Journal: Conference Paper] Scandinavian Journal of Infectious Diseases Supplement. Vol. 22(68)(pp 64-69), 1990. &lt;br&gt;AN: 1990265153&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:38:28 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanellakopoulou K, Giamarellou H</AU>
<TI>Clinical experinece with parenteral and oral ofloxacin in severe infections</TI>
<SO>Scandinavian Journal of Infectious Diseases Supplement</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>68</NO>
<PG>64-9</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:38:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:38:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990265153"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Conte-2001" NAME="Le Conte 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Le Conte P. Simon N. Bourrier P. Merit JB. Lebrin P. Bonnieux J. Potel G. Baron D. [Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. [French] [Clinical Trial. Comparative Study. English Abstract. Journal Article. Multicenter Study. Randomized Controlled Trial] Presse Medicale. 30(1):11-5, 2001 Jan 13. UI: 11210578&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Conte P, Simon N, Bourrier P, Merit JB, Lebrin P, Bonnieux J et al</AU>
<TI>Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin</TI>
<SO>Presse Medicale</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>1</NO>
<PG>11-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11210578"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levtchenko-2001a" NAME="Levtchenko 2001a" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Levtchenko E. Lahy C. Levy J. Ham H. Piepsz A. Treatment of children with acute pyelonephritis: a prospective randomized study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Pediatric Nephrology. 16(11):878-84, 2001 Nov. UI: 11685593&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levtchenko E, Lahy C, Levy J, Ham H, Piepsz A</AU>
<TI>Treatment of children with acute pyelonephritis: a prospective randomized study</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>11</NO>
<PG>878-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11685593"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorian-1994" NAME="Lorian 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Lorian V. Pavletich K. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections. [Journal Article] Drugs Under Experimental &amp;amp; Clinical Research. 20(5):209-14, 1994. &lt;br&gt;UI: 7875058&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorian V, Pavletich K</AU>
<TI>Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: A study of 291 infections</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>5</NO>
<PG>209-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7875058"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matilla-1982" MODIFIED="2008-06-11 16:38:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Matilla 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-11 16:38:43 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Matilla J. Kyronseppa H. Pettersson T. et al. Parenteral cephalexin lysinate followed by oral cephalexin in the treatment of serious pulmonary and urinary tract infections - a comparison with cephradine. [Journal] Drugs Under Experimental &amp;amp; Clinical Research. Vol. 8(5)(pp 493-498), 1982. AN: 1983059737&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:38:43 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matilla J, Kyronseppa H, Pettersson T et al</AU>
<TI>Parenteral cephalexin lysinate followed by oral cephalexin in the treatment of serious pulmonary and urinary tract infections - a comparison with cephradine</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>1982</YR>
<VL>8</VL>
<NO>5</NO>
<PG>493-8</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:38:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:38:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1983059737"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michaelis-1993" MODIFIED="2008-06-11 16:38:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Michaelis 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-11 16:38:54 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Michaelis WE. Bischoff W. Braun HP. Bruehl P. Gerhardts W. Hochberg K. Naber K. Westenfelder M. Combined intravenous and oral treatment in complicated UTI: Lomefloxacin vs ciprofloxacin. [Journal: Conference Paper] Drugs. Vol. 46(SUPPL. 3)(pp 348), 1993. AN: 1993243057&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:38:54 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michaelis WE, Bischoff W, Braun HP, Bruehl P, Gerhardts W, Hochberg K et al</AU>
<TI>Combined intravenous and oral treatment in complicated UTI: Lomefloxacin vs ciprofloxacin [abstract]</TI>
<SO>Drugs</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>Suppl 3</NO>
<PG>348</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:38:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:38:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1993243057"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolle-1991" NAME="Nicolle 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Nicolle LE. Degelau J. Alessi P. Cullison J. Meyers B. Ofloxacin use in a geriatric population. [Clinical Trial. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Chemotherapy. 37 Suppl 1:49-54, 1991. UI: 2049965&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE, Degelau J, Alessi P, Cullison J, Meyers B</AU>
<TI>Ofloxacin use in a geriatric population</TI>
<SO>Chemotherapy</SO>
<YR>1991</YR>
<VL>37 Suppl 1</VL>
<PG>49-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2049965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paladino-1991" NAME="Paladino 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Paladino JA. Sperry HE. Backes JM. Gelber JA. Serrianne DJ. Cumbo TJ. Schentag JJ. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] American Journal of Medicine. 91(5):462-70, 1991 Nov. UI: 1951408&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne DJ, Cumbo TJ et al</AU>
<TI>Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91</VL>
<NO>5</NO>
<PG>462-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1951408"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peacock-1989" NAME="Peacock 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Peacock JE Jr. Pegram PS. Weber SF. Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] American Journal of Medicine. 87(5A):185S-190S, 1989 Nov 30. UI: 2686421&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peacock Jr JE, Pegram PS, Weber SF, Leone PA</AU>
<TI>Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>185S-190S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2686421"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-1988" MODIFIED="2008-06-11 16:39:08 +1000" MODIFIED_BY="Narelle S Willis" NAME="Raz 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-06-11 16:39:08 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Raz R. Chaimowitsh G. Keness Y. Sudarsky M. Oral ciprofloxacin as a follow-up treatment for complicated urinary tract infections due to organisms resistant to oral antibiotics. [Journal] Urologia. Vol. 55(2)(pp 123-127), 1988. &lt;br&gt;AN: 1988159373&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:39:08 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Chaimowitsh G, Keness Y, Sudarsky M</AU>
<TI>Oral ciprofloxacin as a follow-up treatment for complicated urinary tract infections due to organisms resistant to oral antibiotics</TI>
<SO>Urologia</SO>
<YR>1988</YR>
<VL>55</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:39:08 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:39:08 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1988159373"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robson-1993" MODIFIED="2008-06-11 16:39:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Robson 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-11 16:39:36 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Robson RA. Bailey RR. Lynn KL. Lomefloxacin pharmacokinetics after intravenous and oral administration in patients with acute pyelonephritis. [Journal: Conference Paper] Drugs. Vol. 46(SUPPL. 3)(pp 269), 1993. &lt;br&gt;AN: 1993243011&lt;/p&gt;" NOTES_MODIFIED="2008-06-11 16:39:36 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robson RA, Bailey RR, Lynn KL</AU>
<TI>Lomefloxacin pharmacokinetics after intravenous and oral administration in patients with acute pyelonephritis [abstract]</TI>
<SO>Drugs</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>Suppl 3</NO>
<PG>269</PG>
<IDENTIFIERS MODIFIED="2008-06-11 16:39:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 16:39:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1993243011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Safrin-1988" NAME="Safrin 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Safrin S. Siegel D. Black D. Pyelonephritis in adult women: inpatient versus outpatient therapy. [Comparative Study. Journal Article. Research Support, U.S. Gov't, P.H.S.] American Journal of Medicine. 85(6):793-8, 1988 Dec. UI: 3195603&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Safrin S, Siegel D, Black D</AU>
<TI>Pyelonephritis in adult women: Inpatient versus outpatient therapy</TI>
<SO>American Journal of Medicine</SO>
<YR>1988</YR>
<VL>85</VL>
<NO>6</NO>
<PG>793-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3195603"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sannier-2000" NAME="Sannier 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Sannier N. Le Masne A. Sayegh N. Gaillard JL. Cheron G. Ambulatory management of acute pyelonephritis in children. [Letter] Acta Paediatrica. 89(3):372-3, 2000 Mar. &lt;br&gt;UI: 10772296&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sannier N, Le Masne A, Sayegh N, Gaillard JL, Cheron G</AU>
<TI>Ambulatory management of acute pyelonephritis in children</TI>
<SO>Acta Paediatrica</SO>
<YR>2000</YR>
<VL>89</VL>
<NO>3</NO>
<PG>372-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10772296"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timmerman-1992" NAME="Timmerman 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Timmerman C. Hoepelman I. de Hond J. Boon T. Schreinemachers L. Mensink H. Verhoef J. Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial] Infection. 20(1):34-7, 1992 Jan-Feb. UI: 1563810&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timmerman C, Hoepelman I, de Hond J, Boon T, Schreinemachers L, Mensink H et al</AU>
<TI>Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>1</NO>
<PG>34-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1563810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-12 10:16:45 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2008-06-11 16:40:30 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-06-11 16:39:46 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-1999" MODIFIED="2008-06-11 16:39:48 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gonzalez 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez CM, Schaeffer AJ</AU>
<TI>Treatment of urinary tract infection: what's old, what's new, and what works</TI>
<SO>World Journal of Urology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>6</NO>
<PG>372-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10654368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hansson-1999" NAME="Hansson 1999" TYPE="BOOK_SECTION">
<AU>Hansson S, Jodal U</AU>
<TI>Urinary tract infection</TI>
<SO>Pediatric Nephrology</SO>
<YR>1999</YR>
<PG>835-50</PG>
<EN>4th</EN>
<ED>Barratt TM, Avner ED, HarmanWE</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-06-11 16:39:55 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones-1996" MODIFIED="2008-06-11 16:40:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jones 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jones B, Jarvis P, Lewis JA, Ebbutt AF</AU>
<TI>Trials to assess equivalence: the importance of rigorous methods</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7048</NO>
<PG>36-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8664772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kunin-1994" MODIFIED="2008-06-11 16:40:03 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kunin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kunin CM</AU>
<TI>Urinary tract infections in females</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8054415"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levtchenko-2001" MODIFIED="2008-06-11 16:40:05 +1000" MODIFIED_BY="Narelle S Willis" NAME="Levtchenko 2001" TYPE="JOURNAL_ARTICLE">
<AU>Levtchenko E, Ham HR, Levy J, Piepsz A</AU>
<TI>Attitude of Belgian pediatricians toward strategy in acute pyelonephritis</TI>
<SO>Pedatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>113-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11261676"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Master-List-2007" NAME="Master List 2007" TYPE="OTHER">
<AU>United States Cochrane Center</AU>
<TI>Master list of journals being searched</TI>
<SO>http://apps1.jhsph.edu/cochrane/masterlist.asp</SO>
<YR>(accessed 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCracken-1989" MODIFIED="2008-06-11 16:40:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="McCracken 1989" TYPE="JOURNAL_ARTICLE">
<AU>McCracken GH Jr</AU>
<TI>Options in antimicrobial management of urinary tract infections in infants and children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>8</NO>
<PG>552-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2771540"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Orenstein-1999" MODIFIED="2008-06-11 16:40:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Orenstein 1999" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein R, Wong ES</AU>
<TI>Urinary tract infections in adults</TI>
<SO>American Family Physician</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>5</NO>
<PG>1225-34, 1237</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10088877"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ransley-1981" MODIFIED="2008-06-11 16:40:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ransley 1981" TYPE="JOURNAL_ARTICLE">
<AU>Ransley PG, Risdon RA</AU>
<TI>Reflux nephropathy: effects of antimicrobial therapy on the evolution of the early pyelonephritic scar</TI>
<SO>Kidney International</SO>
<YR>1981</YR>
<VL>20</VL>
<NO>6</NO>
<PG>733-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7038262"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smellie-1994" MODIFIED="2008-06-11 16:40:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Smellie 1994" TYPE="JOURNAL_ARTICLE">
<AU>Smellie JM, Poulton A, Prescod NP</AU>
<TI>Retrospective study of children with renal scarring associated with reflux and urinary infection</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6938</NO>
<PG>1193-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8180534"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stamm-1993" MODIFIED="2008-06-11 16:40:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stamm 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stamm WE, Hooton TM</AU>
<TI>Management of urinary tract infections in adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>18</NO>
<PG>1328-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8413414"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Winberg-1974" MODIFIED="2008-06-11 16:40:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Winberg 1974" TYPE="JOURNAL_ARTICLE">
<AU>Winberg J, Andersen HJ, Bergstrom T, Jacobsson B, Larson H, Lincoln K</AU>
<TI>Epidemiology of symptomatic urinary tract infection in childhood</TI>
<SO>Acta Paediatrica Scandinavica - Supplement</SO>
<YR>1974</YR>
<NO>252</NO>
<PG>1-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4618418"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-12 10:16:45 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Pohl-2001" MODIFIED="2008-06-12 10:16:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Pohl 2001" TYPE="COCHRANE_REVIEW">
<AU>Pohl A, Antes G, Forster J</AU>
<TI>Modes of administration of antibiotics for symptomatic urinary tract infections. (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-06-12 10:16:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-12 10:16:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD003237"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-11 17:18:37 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-11 17:18:37 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Baker-2001">
<CHAR_METHODS>
<P>Prospective RCT at a tertiary care centre.<BR/>No central randomisation.<BR/>Opaque envelopes blindly selected from bin, clinicians blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 34 (group 1), 35 (group 2).<BR/>Gender (F/total): 32/34 (group 1), 30/35 (group 2).<BR/>Age: 6 months to 12 years.<BR/>Fever &gt; 38.0°C, history and physical examination suggesting UTI and positive urine culture from catheter specimen or MSU.</P>
<P>EXCLUSION CRITERIA<BR/>Abnormality of urinary tract, already taking antibiotics, allergy to study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>TREATMENT GROUP 1<BR/>Single shot IM /oral therapy.<BR/>Ceftriaxone IM 50 mg/kg once initially followed by oral trimethoprim 10 mg/kg/d for 10 days.</P>
<P>TREATMENT GROUP 2<BR/>Oral therapy.<BR/>Trimethoprim 10 mg/kg/d for 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical and bacteriological cure after 48 hours.<BR/>2. Bacteriological cure rate after 48 hours.<BR/>3. Reinfection after interval of 1 month (n, %)<BR/>4. Relapse rate after interval of 1 month (n, %).<BR/>5. Adverse events rate (n, %).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 95 patients who met the inclusion criteria, 87 were enrolled (6 gave no consent, 2 were not petitioned).<BR/>Fourteen patients were excluded after randomisation because urine culture was negative.<BR/>Three (group 1) and 1 (group 2) were lost to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Childs-1990">
<CHAR_METHODS>
<P>Prospective RCT.<BR/>Computer-generated randomisation. <BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 19 (group 1), 21 (group 2).<BR/>Gender (M/F): unknown.<BR/>Age: &gt; 18 years.<BR/>Clinical symptoms of severe UTI requiring parenteral antibiotic therapy and a positive urine culture.</P>
<P>EXCLUSION CRITERIA<BR/>Cases of allergy, severe underlying disease, renal impairment, pregnancy, urinary tract obstruction, catheterization.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ciprofloxacin 200 mg twice daily IV for 2 to 5 days, followed by 500 mg twice daily orally for up to 14 days.</P>
<P>GROUP 2<BR/>IV therapy.<BR/>Ceftazidime 500 mg thrice daily for 4 to 9 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical cure rate at end of therapy (clinical cure or improvement at end of therapy, bacteriologic eradication 5 to 9 days after therapy end).<BR/>2. Bacteriological cure rate at end of therapy (clinical cure or improvement at end of therapy, bacteriologic eradication 5 to 9 days after therapy end).<BR/>3. Reinfection rate at end of therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 63 patients enrolled, 23 were excluded from evaluation because of missing/sterile urine culture before or after therapy (20), pathogen resistant to study drug (2) or renal impairment (1).<BR/>Two patients in each group had acute prostatitis, 1 patient in IV group had epididymitis.<BR/>Fifteen patients in each group were classified as having complicated UTI.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-11 17:16:17 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fischbach-1989">
<CHAR_METHODS>
<P>Prospective RCT.<BR/>Randomisation table.<BR/>No information whether ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-11 17:16:17 +1000" MODIFIED_BY="Narelle S Willis">
<P>INCLUSION CRITERIA<BR/>Number: 10 (group 1), 10 (group 2).<BR/>Age: children, age not stated.<BR/>Gender (F/total): 8/10 (group 1), 7/10 (group 2).<BR/>Less than 1 year with fever &gt; 38.5°C, pyuria, bacteriuria, positive urine culture, ESR &gt; 35 mm/h, elevated CRP and orosomucoid.</P>
<P>EXCLUSION CRITERIA<BR/>Beta lactam allergy, antibiotic therapy 72 hours before study inclusion, impaired renal function or post-op infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>amoxicillin/clavulanate acid 100 mg/kg/d IV for 7 days followed by 50 mg/kg/d po for 7 days.</P>
<P>GROUP 2<BR/>IV therapy.<BR/>Cefotaxime 100 mg/kg/d IV for 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Number of patients with fever &gt; 48 hours.<BR/>2. Number of patients with bacteriological cure after 48 hours.<BR/>3. Number of patients with reinfection after interval (7 days after end of therapy).<BR/>4. Number of patients with relapse after interval (7 days after end of therapy).<BR/>5. Number of patients with adverse events.<BR/>6. Lab parameter. <BR/>7. No treatment failure rate.<BR/>8. No clinical cure rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No patient flow diagram.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-11 17:18:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Francois-1997">
<CHAR_METHODS>
<P>Prospective, multicentre RCT.<BR/>Randomisation per telephone call (Minitel) at day 4.<BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-11 17:18:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>INCLUSION CRITERIA<BR/>Number: 63 (group 1), 65 (group 2).<BR/>Age: 6 months to 10 years.<BR/>Gender (F/total): 57/63 (group 1), 57/65 (group 2).<BR/>Fever &gt; 38.0°C, elevated CRP, pyuria, bacteriuria, positive urine culture with germ sensitive to ceftriaxon, netilmicin and cefixime.</P>
<P>EXCLUSION CRITERIA<BR/>Allergy to antibiotics, catheterization, complicated UTI, immune deficiency, kidney failure, urine culture not sterile after 48 hours of treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ceftriaxon 50 mg/kg/d IV and netilmicin 6 to 7.5 mg/kg/d IV for 4 days followed by cefixime 8 mg/kg/d PO for 6 days.</P>
<P>GROUP 2<BR/>IV/IM therapy.<BR/>Ceftriaxon/netilmicin for 4 days followed by ceftriaxon 50 mg/kg/d IM or IV for 6 days.</P>
<P>CO INTERVENTIONS<BR/>Both groups received antibiotic prophylaxis for 20 days (nitroxoline).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Cure rate defined as no clinical signs and bacteriological eradication 48 hours after end of treatment (n, %) and after interval of 20 to 30 days.<BR/>2. Reinfection rate after interval (20 to 30 days) (n, %).<BR/>3. Adverse events rate (n, %).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 169 patients who met the inclusion criteria, 147 were randomised.<BR/>Seven (group 1) and 12 (group 2) were excluded from analyses because there was no evaluable result.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gok-2001">
<CHAR_METHODS>
<P>Prospective RCT at Paediatric University Hospital. <BR/>No information on method of randomisation or type of analysis (ITT?)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 25 (group 1), 29 (group 2).<BR/>Age: 2 to 13 years, mean age 6.6 ± 3.3 years.<BR/>Gender (F/total): 20/25 (group 1) 24/29 (group 2).<BR/>Symptoms of UTI and pyuria, bacteriuria and positive urine culture (clean catch urine) without antibiotic prophylaxis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Oral therapy.<BR/>Cefixime 8 mg/kg/d for 10 days.</P>
<P>GROUP 2<BR/>IM switch therapy.<BR/>Ceftizoxime IM 50 mg/kg twice daily for 2 days followed by oral cefixime for 8 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Cure rate: defined as resolution of all signs and symptoms and eradication of pathogen at end of treatment and after 3 weeks.<BR/>2. Reinfection rate: defined as development of new or worsened signs or symptoms and infection with a new pathogen in patients who had been cured at end of treatment and after 3 weeks.<BR/>3. Relapse: defined as eradication of baseline pathogen with reappearance of same pathogen at end of treatment and after 3 weeks.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Symptoms of UTI not further specified.<BR/>No patient flow diagram.<BR/>Adverse events: one patient developed diarrhoea caused by cefixime, but no information to which group this patient belonged.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hoberman-1999">
<CHAR_METHODS>
<P>Prospective, multicentre RCT.<BR/>Computer-generated randomisation list.<BR/>Stratification based on age and duration of fever.<BR/>ITT.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 153 in each group. <BR/>Gender (F/total): 137/153 (group 1), 136/153 (group 2)<BR/>Age: 1 to 24 months.<BR/>Fever &gt; 38.3°C, pyuria, bacteriuria and positive urine culture from catheter specimen.</P>
<P>EXCLUSION CRITERIA<BR/>Unequivocal source for fever, history of UTI or abnormality of urinary tract.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Cefotaxime IV 200 mg/kg/d for 3 days or until afebrile &gt; 24 hours, followed by oral cefixime 8 mg/kg/d for 14 days.</P>
<P>GROUP 2<BR/>Oral therapy.<BR/>Cefixime 16 mg/kg/d initially followed by 8 mg/kg/d for 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Cessation of fever (hours, mean ± SD).<BR/>2. Cure rate defined as resolution of clinical signs and symptoms and sterilization of urine (obtained in 291/306 children) after 24 hours.<BR/>3. Reinfection rate after interval of 6 months (n, %).<BR/>4. DMSA renal scan after 0.5 year.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Three children were not randomised because they were deemed too sick.<BR/>One child in the oral group was unable to tolerate oral drugs and was given IV drugs.<BR/>Children between 4 to 8 weeks of age and children who needed IV drip were kept at hospital, but treated orally according to protocol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Millar-1995">
<CHAR_METHODS>
<P>Prospective RCT at University hospital.<BR/>Random number table used to create sealed, opaque envelopes, randomisation in blocks of 6, envelopes kept separately.<BR/>ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 60 pregnant women in each group. <BR/>Gestational week &lt; 24 weeks, with fever &gt; 38.4°C, flank pain, pyuria.</P>
<P>EXCLUSION CRITERIA<BR/>Sepsis, respiratory insufficiency, fever &gt; 39.8°C, RR &lt; 90/50 mm Hg, creatinine &gt; 1.4 mg/dL, allergy to cephalosporins, inability to tolerate oral intake, serious medical illness, known renal or urologic problems, antibiotic therapy during 2 preceding weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Single shot IM/oral therapy.<BR/>Ceftriaxone 1 g IM twice within 18 to 36 hours, followed by cephalexin 500 mg PO 4 times/d for 10 days.</P>
<P>GROUP 2<BR/>IV switch therapy.<BR/>Cefazolin 1 g three times/d until afebrile for 48 hours, followed by cephalexin 500 mg PO 4 times/d for 10 days.</P>
<P>CO INTERVENTIONS<BR/>All patients received oral prophylaxis with nitrofurantoin till 6 weeks postpartum.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical cure during first 3 days.<BR/>2. Bacterial cure at end of therapy.<BR/>3. Adverse events rate (minor and major combined).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 120 patients enrolled, 1 patient each group had negative urine culture at beginning, 9 patients had no urine culture at beginning, 2 patients of Group 1 were given IV therapy because of sepsis, but all were analysed according to randomisation nevertheless (ITT).<BR/>Seven (group 1) and 3 (group 2) had no urine culture at end of therapy (of those, 3 were clinically doing well).<BR/>Number of patients with clinical cure at end of therapy not clearly presented.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mombelli-1999">
<CHAR_METHODS>
<P>Prospective, multicentre RCT at 4 community care centres.<BR/>Randomisation at each centre by sealed envelopes/code list.<BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 72 (group 1), 69 (group 2).<BR/>Gender (F/total): (44/72 (group 1), 39/69 (group 2).<BR/>Age: &gt;18 years.<BR/>Fever &gt; 37.5°C, pyuria, bacteriuria, leukocytosis and signs of UTI or complicating urologic conditions. Included also if culture was negative because of recent antibiotic treatment (2 in each group) or contaminated with mixed flora superimposed on one pathogen having at least 100,000 CFU (4 (group 1), 2 (group 2)).</P>
<P>EXCLUSION CRITERIA<BR/>Ciprofloxacin allergy, inability to take oral medicine, severe sepsis, elevated creatinine levels, renal obstruction, pregnancy, high-risk condition (e.g. agranulocytosis).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ciprofloxacin IV 400 mg/d for 72 hours or until afebrile for 24 hours followed by ciprofloxacin PO 1,000 mg/d.</P>
<P>GROUP 2<BR/>Oral therapy.<BR/>Ciprofloxacin 400 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Cessation of fever (days, mean, CI).<BR/>2. Combined clinical and bacteriological cure rate under therapy (after 3 to 5 days of therapy).<BR/>3. Adverse events rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 163 enrolled, 22 patients (11/group) were excluded from analysis. Of those, 19 patients did not fulfil inclusion criteria retrospectively, 2 had incomplete outcome data, 1 withdrew consent. 2 patients of each group had received other antibiotics within 24 hours before study begin and had negative urine culture at inclusion.<BR/>SD calculated based on 95% CI.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Montini-2007">
<CHAR_METHODS>
<P>Prospective multicentre RCT.<BR/>Computer generated randomisation list with stratification for hospital, sex and age, block randomisation.<BR/>No information whether ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 185 (group 1), 202 (group 2).<BR/>Gender: 244 females.<BR/>Age: 2 months to 6 years with normal kidney function.<BR/>First UTI defined as fever, 2 consecutive positive urinalysis, 2 positive urine cultures, high blood inflammation indices.</P>
<P>EXCLUSION CRITERIA<BR/>Excluded in case of urinary tract malformation, serious illness, hypersensitivity to antibiotics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Oral therapy.<BR/>amoxicillin/clavulanic acid 50 mg/kg/d for 10 days.</P>
<P>GROUP 2<BR/>IV switch therapy.<BR/>Ceftriaxon 50 mg/kg/d until cessation of fever followed by amoxicillin/clavulanic acid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Cessation of fever (hours mean, SD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract only plus information from www.clinicaltrials.gov.<BR/>At time of publication, 88% of required population was enrolled</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neuhaus-2008">
<CHAR_METHODS>
<P>Prospective multicentre RCT.<BR/>Computer generated randomisation list, sealed envelopes.<BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 78 (group 1), 72 (group 2).<BR/>Gender (F/M): unknown.<BR/>Age: 6 months to 16 years.<BR/>Fever &gt; 38°C, CRP &gt; 10 mg/L, positive urine culture (catheter urine) and positive DMSA scintigraphy at beginning (signs of pyelonephritis).</P>
<P>EXCLUSION CRITERIA<BR/>Normal scintigraphy, sepsis, complex urinary abnormalities.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Oral therapy.<BR/>Ceftibuten 9 mg/kg/d PO for 14 days.</P>
<P>GROUP 2<BR/>IV switch therapy.<BR/>Ceftriaxone 50 mg/kg IV for 3 days followed by ceftibuten for 11 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Number of patients with renal scarring (DMSA) after 6 months.<BR/>2. Adverse events rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 365 children initially enrolled and randomised, 346 had an acute DMSA scan.<BR/>Children excluded because of normal DMSA scan (127).<BR/>Follow-up scan and included in analysis (152).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Noorbakhsh-2004">
<CHAR_METHODS>
<P>Prospective RCT in a tertiary care centre.<BR/>Randomisation list kept with principal investigator.<BR/>No ITT.</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 24 (group 1), 30 (group 2).<BR/>Gender (F/M): unknown.<BR/>Age: &lt;/= 10 years.<BR/>Fever, flank pain, pyuria and positive urine culture. </P>
<P>EXCLUSION CRITERIA<BR/>Severe allergy to study therapy, obstructive uropathy, renal abscess, immune-compromising disease, acute hepatic failure, clinical signs of sepsis, requirement for dialysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ceftriaxone IV 50 mg/kg/d for 2 to 3 days, then cefixime 8 mg/kg/d for 8 to 12 days.</P>
<P>GROUP 2<BR/>IV therapy.<BR/>Amikacin 15 mg/kg/d or gentamicin 3 mg/kg/d with ampicillin 100 mg/kg/d for 7 to 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Combined clinical and microbiological cure rate at end of therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 30/30 patients enrolled, only 24 (group 1) received switch therapy.<BR/>The other 6 were treated IV because of lack of cefixime. These patients were not added to analysis (personal communication of author)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Puppo-1989">
<CHAR_METHODS>
<P>Prospective RCT.<BR/>Randomisation method: not stated.<BR/>ITT: unclear (not stated whether 100 patients were randomised, 18 excluded afterwards, or 100 patients assessed, 18 excluded and 82 randomised).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 18 (group 1), 20 (group 2).<BR/>Gender (F/total): 15/22 females in total study population.<BR/>Age: &gt; 18 years.<BR/>Clinical symptoms of severe UTI/ pyelonephritis and positive urine culture (24/20 adults with mild UTI/cystitis, not included in review).</P>
<P>EXCLUSION CRITERIA<BR/>Hypersensitivity to drugs, pregnancy, breast feeding, severe liver or kidney disease. 78 (5% group 1, /75% group 2) had complicated pyelonephritis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Oral therapy.<BR/>Norfloxacin 400 mg twice daily for 7 days.</P>
<P>GROUP 2<BR/>IM therapy.<BR/>Aztreonam 1 g IM twice daily for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Bacteriological cure rate at end of treatment and after 4 week interval (n, %).<BR/>2. Other outcomes not differentiated in pyelonephritis and cystitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 100 enrolled, 18 patients were excluded before or after randomisation (unclear).<BR/>Only patients with pyelonephritis included in review (38), patients with cystitis (44) not included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Regnier-1989">
<CHAR_METHODS>
<P>Prospective multicentre RCT.<BR/>Randomisation table in blocks of 4, stratification according to centre.<BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 47 (group 1), 48 (group 2).<BR/>Gender (F/total): unknown, but 4 times more females<BR/>Age: &gt; 15 years.<BR/>Severe UTI defined as fever, bacteriuria, positive urine culture and pyuria or at least one clinical sign or 2 positive urine cultures.<BR/>Severity defined as either fever &gt; 39°C, age &gt; 65 years or pre-existing nephro-urological disease or positive haemoculture. </P>
<P>EXCLUSION CRITERIA<BR/>pregnancy, breast feeding, insufficient contraception, cephalosporin allergy, renal or hepatic failure, or other chronic disease, antibiotics within 48 hours.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ceftriaxone 2 g/d for 4 days IV followed by oral cefixime 200 mg twice daily for 11 days.</P>
<P>GROUP 2<BR/>Parenteral therapy.<BR/>IV ceftriaxone 2 g/d for 4 days followed by IM or IV ceftriaxone 1 g/d for 11 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical cure rate at end of therapy.<BR/>2. Clinical and bacteriological cure rate at the end of treatment and after interval of 30 to 45 days.<BR/>3. Reinfection rate at end of treatment and after interval.<BR/>4. Relapse rate after interval.<BR/>5. Adverse events rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 97 patients enrolled, 2 patients of parenteral group were excluded from analysis because of negative urine culture at beginning.<BR/>No urine culture at the end of treatment in 11/12 patients (1/12 complete loss to follow-up) and therefore exclusion from most of the outcomes.<BR/>8/6 patients lost to follow-up after 30 to 45 days.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanchez-2002">
<CHAR_METHODS>
<P>Prospective RCT at a tertiary care centre.<BR/>Randomisation based on computer generated numbers.<BR/>No ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 51 (group 1), 54 (group 2).<BR/>Gender (F/M): all women.<BR/>Age: 18 to 75 years.<BR/>Diagnosis of UTI defined as fever &gt; 38°C, flank pain and pyuria.</P>
<P>EXCLUSION CRITERIA<BR/>Pregnancy, catheterisation, preceding antibiotic treatment, complicated UTI, sterile urine culture at beginning, hypersensitivity to cephalosporins.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>Single shot IV/oral therapy.<BR/>Ceftriaxone 1 g IV, then cefixime 400 mg or other oral antibiotic according to results of urine culture for 10 days.</P>
<P>GROUP 2<BR/>IV switch therapy.<BR/>Ceftriaxone 1 g/d IV until results of urine culture then oral antibiotics for a total of 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical cure rate under therapy (after 3 days).<BR/>2. Clinical cure rate at end of therapy (after 10 days).<BR/>3. Bacterial cure rate under therapy (after 3 days).<BR/>4. Duration of fever (days).<BR/>5. Duration of clinical symptoms (days).<BR/>6. Adverse events rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 144 patients enrolled with clinical symptoms of UTI, 51 (group 1) and 54 (group 2) had a positive urine culture (others were excluded after randomisation).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vilaichone-2001">
<CHAR_METHODS>
<P>Prospective RCT at a tertiary care centre.<BR/>Randomised in blocks of 4, method not stated.<BR/>ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>INCLUSION CRITERIA<BR/>Number: 18 (group 1), 18 (group 2).<BR/>Gender (F/total): 9/18 (group 1) 8/18 (group 2).<BR/>Age: 1 month to 15 years.<BR/>Fever, &gt; 38°C or subnormal temperatures in small infants, pyuria and/or bacteriuria and a positive urine culture from MSU or bag and a positive 99mTc-DMSA scan proving pyelonephritis.</P>
<P>EXCLUSION CRITERIA<BR/>History of previous UTI, anatomic abnormalities, neurogenic bladder, kidney failure, allergy to cephalosporin or penicillin, systemic antibiotics within 48 hours, chronic disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>GROUP 1<BR/>IV switch therapy.<BR/>Ceftriaxon IV 75 mg/kg/d until afebrile &gt; 24 to 48 hours, followed by oral ceftibuten 9 mg/kg/d for 10 days.</P>
<P>GROUP 2<BR/>IV therapy.<BR/>Ceftriaxone IV 75 mg/kg/d for 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Bacteriological cure rate at end of therapy (day 14).<BR/>2. Clinical cure rate after interval of 6 months.<BR/>3. Bacteriological cure rate after interval of 6 months.<BR/>4. Reinfection rate after 6 months (n, %).<BR/>5. DMSA renal scan after 0.5 year.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Of 100 patients, 64 were excluded before randomisation because of recurrent UTI (9), anatomical abnormalities (5), chronic disease (2), failure to notify (4), normal DMSA scan at beginning (18), negative urine culture (26).<BR/>Hospitalisation rate cannot be compared because only mean (no SD) is given.<BR/>Adverse events rate only given for IV switch group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>UTI - urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abraham-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (retrospective cohort study).<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ahmetagic-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Includes patients with sepsis from age 0 to 96 years. No separate data for patients with UTI. No clear inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angel-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Unclear data presentation of 102 patients screened, 90 (45/45) were randomised into group 1(IV switch therapy) or group 2 (oral therapy). Three patients of group 1 and 10 patients of group 2 were excluded afterwards because of positive blood culture and subsequent IV therapy. Patients with a negative urine culture (5/90). Only 39 in group 1 and 33 in group 2 had a urine culture at the end of therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benador-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares 2 switch therapies with different duration of IV antibiotics (3 days IV then 12 days PO versus 10 days IV then 5 days PO).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buchi-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bunnag-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cherubin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Includes patients with complicated UTI and resistant organisms. Mild UTI (cystitis), only 28% of patients had fever at inclusion, only 28% are classified as having pyelonephritis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Concia-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>No inclusion criteria, unclear data presentation. Compares switch therapy with IV therapy, but only 19/23 patients received switch therapy, 4 patients of switch therapy group received IV therapy only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cox-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Includes only patients with nosocomially acquired UTI. Only 17% had E. coli infection, but in 31% Pseudomonas could be isolated. Also, most patients had a Foley catheter in place when becoming infected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cox-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Includes only patients with complicated UTI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daly-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Esposito-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Includes patients with mild to moderate UTI not further specified, probably rather lower than upper UTI (no clear inclusion criteria, no baseline characteristics table). All included patients had liver cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fang-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compared oral therapy with ciprofloxacin and IV therapy with aminoglycosides in patients with complicated UTI (inclusion criteria: anatomic or functional abnormality of urinary tract).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fass-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stratified RCT.<BR/>Compares ceftazidime IV versus ciprofloxacin IV/PO in 72 patients, among those 31 patients with UTI. Many of the patients in the IV group were switched to an oral beta-lactam. No randomisation within UTI strata (23 ceftazidime IV, 8 ciprofloxacin IV/PO).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gangji-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Randomised 89 patients with septicaemia and among those 33 patients with UTI. No separate outcome data for UTI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaut-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Only 5 with UTI. Patients with UTI were only included if infection was caused by P. aeruginosa or any other organism resistant to conventional antibiotics and was either complicated or severe. Typical UTI = exclusion to study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gelfand-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (sequential therapy group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giamarellou-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Patients with UTI (28/103). Comparison between ceftazidime IV or IM and pefloxacin IV or PO or sequential, but results are not documented according to mode of application.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harding-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares oral ciprofloxacin versus standard parenteral therapy in patients with complicated UTI (inclusion criteria: complicated UTI, i.e. documented anatomical or functional abnormalities, presence of chronic catheter or recurrent episodes of UTI).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalager-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares sequential therapy and IV therapy in RCT including patients with systemic infections, among those 51(?) patients with UTI. Data presentation unclear and contradictory, not possible to extract data for UTI only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanellakopoulou-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Le-Conte-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares ciprofloxacin plus placebo vs ciprofloxacin plus tobramycin single shot. Ciprofloxacin was given IV in 15% and orally in 85% (in both arms).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levtchenko-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares 2 switch therapies with different duration of IV antibiotics (3 days IV then 15 d PO versus 7 days IV then 14 days PO).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lorian-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (retrospective cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matilla-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares two different sequential therapies: cephalexin versus cephradine, both initially as parenteral treatment and then as oral treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michaelis-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares two different sequential therapies: lomefloxacin versus ciprofloxacin, both initially as parenteral treatment and then as oral treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nicolle-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares oral or IV ofloxacin versus standard care in pneumonia, UTI and skin infection. Five patients with UTI, all randomised to ofloxacin, none randomised to standard care.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paladino-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares IV antibiotics versus IV switch therapy in serious infections. Randomisation was not infection-specific, most patients had previous antibiotic treatment, 11 patients with UTI were randomised to IV therapy, 8 to switch therapy. UTI was secondary infection in 3 patients, 5 patients had complicated UTI, 5 patients had bacteraemia, a primary focus and UTI as secondary focus simultaneously. Antibiotic treatment before enrolment (51/103).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peacock-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares sequential ciprofloxacin (IV and oral) with ceftazidime (followed by oral antibiotic) in severe infections. Number receiving oral antibiotics: 63% in ciprofloxacin group and 55% in ceftazidime group. No separation of results according to application modes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raz-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares IV switch therapy and IV therapy in patients with complicated UTI (inclusion criteria: complicated UTI without further definition). Enrolled were patients with prostatic obstruction, cancer, kidney stones.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robson-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (pharmacokinetic study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Safrin-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (retrospective cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sannier-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT (retrospective study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Timmerman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT.<BR/>Compares IV switch therapy and IV therapy in patients with complicated UTI defined as anatomical or functional abnormality of the urinary tract, urinary tract instrumentation and/or a serious illness.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Baker-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Childs-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fischbach-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Francois-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gok-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hoberman-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Millar-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mombelli-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Montini-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Neuhaus-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Noorbakhsh-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Puppo-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Regnier-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vilaichone-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-07-22 16:16:37 +1000" MODIFIED_BY="Gail Y Higgins" NO="1">
<TITLE>Methodological quality of included studies</TITLE>
<TABLE COLS="8" ROWS="16">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Concealed allocation</P>
</TH>
<TH>
<P>Blinding patients</P>
</TH>
<TH>
<P>Blinding clinicians</P>
</TH>
<TH>
<P>Blinding outcomes</P>
</TH>
<TH>
<P>Intention-to-treat</P>
</TH>
<TH>
<P>Enrolled/evaluated</P>
</TH>
<TH>
<P>Dropouts</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Baker-2001" TYPE="STUDY">Baker 2001</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>87/69</P>
</TD>
<TD>
<P>4/73 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Childs-1990" TYPE="STUDY">Childs 1990</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>63/40</P>
</TD>
<TD>
<P>7/63 (11%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fischbach-1989" TYPE="STUDY">Fischbach 1989</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>?/20</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Francois-1997" TYPE="STUDY">Francois 1997</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated (blinded in case of ambiguity and resolution by third party)</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>147/128</P>
</TD>
<TD>
<P>Group 1: 7 (11%)<BR/>Group 2: 12 (18%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gok-2001" TYPE="STUDY">Gok 2001</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>?/54</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hoberman-1999" TYPE="STUDY">Hoberman 1999</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>306/306-272 (depending on outcome)</P>
</TD>
<TD>
<P>Group 1: 21 (14%) Group 2: 13 (8%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Millar-1995" TYPE="STUDY">Millar 1995</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>120/110</P>
</TD>
<TD>
<P>Group 1: 3 (5%) Group 2: 7 (12%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mombelli-1999" TYPE="STUDY">Mombelli 1999</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>163/141</P>
</TD>
<TD>
<P>2/141 (1%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Montini-2007" TYPE="STUDY">Montini 2007</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>387(=88% sample size)/387</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Neuhaus-2008" TYPE="STUDY">Neuhaus 2008</LINK>
</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>365/152</P>
</TD>
<TD>
<P>86/365 (24%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Noorbakhsh-2004" TYPE="STUDY">Noorbakhsh 2004</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>60/54</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Puppo-1989" TYPE="STUDY">Puppo 1989</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No (Unclear)</P>
</TD>
<TD>
<P>100/82 (number included in this review: 38)</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Regnier-1989" TYPE="STUDY">Regnier 1989</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>97/95 (81 after interval)</P>
</TD>
<TD>
<P>Group 1: 6 (12.5%) Group 2: 8 (17%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sanchez-2002" TYPE="STUDY">Sanchez 2002</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>144/105</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vilaichone-2001" TYPE="STUDY">Vilaichone 2001</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>36/36</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-11 17:15:30 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2008-06-11 17:15:30 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Switch versus parenteral therapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Fever after 48 hours</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="8322" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Fischbach-1989" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological cure under therapy</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1493585181013943" CI_START="0.5371230378100778" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.060455518807110926" LOG_CI_START="-0.26992621984713694" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="8323" O_E="0.0" SE="0.19406786870148712" STUDY_ID="STD-Fischbach-1989" TOTAL_1="9" TOTAL_2="10" VAR="0.03766233766233765" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.33875292208691804" CI_END="1.1001031847615836" CI_START="0.9353372368210764" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0143803394452031" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.041433421949949645" LOG_CI_START="-0.029031775561552065" LOG_EFFECT_SIZE="0.006200823194198745" METHOD="MH" MODIFIED="2008-06-11 16:50:38 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.5605501176073999" P_Q="1.0" P_Z="0.7301339839506064" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="71" WEIGHT="100.0" Z="0.3449473091492143">
<NAME>Clinical cure at end of treatment</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.195239321585051" CI_START="0.915992670496134" EFFECT_SIZE="1.0463414634146342" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.07745487234489949" LOG_CI_START="-0.038108001414921926" LOG_EFFECT_SIZE="0.01967343546498877" ORDER="8324" O_E="0.0" SE="0.06788220409197003" STUDY_ID="STD-Childs-1990" TOTAL_1="19" TOTAL_2="21" VAR="0.004607993632383872" WEIGHT="37.18028212680204"/>
<DICH_DATA CI_END="1.1032641742219338" CI_START="0.8990304762398013" EFFECT_SIZE="0.9959257582616569" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="47" LOG_CI_END="0.04267951576738571" LOG_CI_START="-0.046225585865843084" LOG_EFFECT_SIZE="-0.0017730350492286934" ORDER="8325" O_E="0.0" SE="0.05222329678670932" STUDY_ID="STD-Regnier-1989" TOTAL_1="47" TOTAL_2="50" VAR="0.002727272727272724" WEIGHT="62.81971787319796"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0924145169188633" CI_END="1.132615925264311" CI_START="0.9249385907961172" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0235234134240467" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" I2="8.459656612722142" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.054082663776286045" LOG_CI_START="-0.03388710030280658" LOG_EFFECT_SIZE="0.010097781736739692" METHOD="MH" NO="4" P_CHI2="0.2959373210658248" P_Q="1.0" P_Z="0.6527417269134869" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="6.332905661648496E-4" TOTALS="YES" TOTAL_1="37" TOTAL_2="39" WEIGHT="99.99999999999999" Z="0.44995661259161884">
<NAME>Bacteriological cure at end of treatment</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.355727833233566" CI_START="0.9010707151196966" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.13217251225331925" LOG_CI_START="-0.045241124691138584" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="8326" O_E="0.0" SE="0.10421364855284106" STUDY_ID="STD-Childs-1990" TOTAL_1="19" TOTAL_2="21" VAR="0.01086048454469507" WEIGHT="23.231612930408925"/>
<DICH_DATA CI_END="1.1102005841375073" CI_START="0.9007381317285831" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.04540145150208338" LOG_CI_START="-0.04540145150208339" LOG_EFFECT_SIZE="0.0" ORDER="8327" O_E="0.0" SE="0.05333807470626661" STUDY_ID="STD-Vilaichone-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.002844950213371278" WEIGHT="76.76838706959106"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1358859225840368" CI_END="1.036437317962514" CI_START="0.9442400643481241" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9892652019583633" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="141" I2="4.333254650796221" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.015543041802611799" LOG_CI_START="-0.024917576287554907" LOG_EFFECT_SIZE="-0.00468726724247155" METHOD="MH" NO="5" P_CHI2="0.37114533833015095" P_Q="1.0" P_Z="0.6497464791315111" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.1206440672202177E-4" TOTALS="YES" TOTAL_1="142" TOTAL_2="152" WEIGHT="99.99999999999999" Z="0.4541144161804761">
<NAME>Clinical and bacteriological cure at end of treatment</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.355727833233566" CI_START="0.9010707151196966" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.13217251225331925" LOG_CI_START="-0.045241124691138584" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="8328" O_E="0.0" SE="0.10421364855284106" STUDY_ID="STD-Childs-1990" TOTAL_1="19" TOTAL_2="21" VAR="0.01086048454469507" WEIGHT="5.101438094529815"/>
<DICH_DATA CI_END="1.0276790937961793" CI_START="0.94221027523769" EFFECT_SIZE="0.9840171755725191" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="65" LOG_CI_END="0.011857521710843371" LOG_CI_START="-0.025852163890296046" LOG_EFFECT_SIZE="-0.006997321089726333" ORDER="8329" O_E="0.0" SE="0.02215085598806353" STUDY_ID="STD-Francois-1997" TOTAL_1="63" TOTAL_2="65" VAR="4.9066042100393E-4" WEIGHT="80.38128268086986"/>
<DICH_DATA CI_END="1.3824712540234527" CI_START="0.8653265368219408" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.14065610970636783" LOG_CI_START="-0.06281997764562851" LOG_EFFECT_SIZE="0.03891806603036966" ORDER="8330" O_E="0.0" SE="0.11952286093343932" STUDY_ID="STD-Noorbakhsh-2004" TOTAL_1="24" TOTAL_2="30" VAR="0.014285714285714277" WEIGHT="3.8961777678241734"/>
<DICH_DATA CI_END="1.0826697510098786" CI_START="0.8181748385993699" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.034496003082845846" LOG_CI_START="-0.0871538805275441" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="8331" O_E="0.0" SE="0.07145774380937871" STUDY_ID="STD-Regnier-1989" TOTAL_1="36" TOTAL_2="36" VAR="0.0051062091503268" WEIGHT="10.621101456776149"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection at end of treatment</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.717678397266763" CI_START="0.14886095178460348" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8272192085506513" LOG_CI_START="-0.8272192085506513" LOG_EFFECT_SIZE="0.0" ORDER="8332" O_E="0.0" SE="0.97182531580755" STUDY_ID="STD-Regnier-1989" TOTAL_1="36" TOTAL_2="36" VAR="0.9444444444444444" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.280797935199783" CI_END="1.1119726473045954" CI_START="0.8886236840832682" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9940448835176581" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="102" I2="39.03922035118537" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.04609410444857317" LOG_CI_START="-0.051282115887406686" LOG_EFFECT_SIZE="-0.002594005719416719" METHOD="MH" MODIFIED="2008-06-11 17:14:43 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.19390284160566462" P_Q="0.37852700763947333" P_Z="0.9168336832064072" Q="0.775480406686421" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0043423790875717775" TOTALS="YES" TOTAL_1="106" TOTAL_2="113" WEIGHT="100.0" Z="0.10442298475347908">
<NAME>Clinical and bacteriological cure after interval</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0631632162996498" CI_END="1.1003577303545262" CI_START="0.9562949662003812" DF="1" EFFECT_SIZE="1.025800447727388" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="68" I2="5.941064864855843" ID="CMP-001.07.01" LOG_CI_END="0.04153389885107653" LOG_CI_START="-0.01940813028166044" LOG_EFFECT_SIZE="0.01106288428470805" MODIFIED="2008-06-11 17:14:33 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.30249522633917625" P_Z="0.47671900099149367" STUDIES="2" TAU2="3.572952302301033E-4" TOTAL_1="67" TOTAL_2="71" WEIGHT="82.5843955195374" Z="0.7115895243965317">
<NAME>Paediatric studies</NAME>
<DICH_DATA CI_END="1.1078103707660432" CI_START="0.9726980030770532" EFFECT_SIZE="1.0380582524271844" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="51" LOG_CI_END="0.04446542647719637" LOG_CI_START="-0.012021975718541581" LOG_EFFECT_SIZE="0.016221725379327392" ORDER="8333" O_E="0.0" SE="0.033180979666926964" STUDY_ID="STD-Francois-1997" TOTAL_1="49" TOTAL_2="53" VAR="0.0011009774116570205" WEIGHT="60.105505287165904"/>
<DICH_DATA CI_END="1.1473357311614967" CI_START="0.7720609798251301" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.05969051890911177" LOG_CI_START="-0.11234839635381014" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="8334" O_E="0.0" SE="0.10105651043180543" STUDY_ID="STD-Vilaichone-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.0102124183006536" WEIGHT="22.478890232371484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1625289894333297" CI_START="0.7257778953252427" DF="0" EFFECT_SIZE="0.918552036199095" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.06540379149227324" LOG_CI_START="-0.13919626303606888" LOG_EFFECT_SIZE="-0.0368962357718978" MODIFIED="2008-06-11 17:14:43 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.47963224980331354" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="42" WEIGHT="17.41560448046261" Z="0.7068941740482347">
<NAME>Adult studies</NAME>
<DICH_DATA CI_END="1.1625289894333297" CI_START="0.7257778953252427" EFFECT_SIZE="0.918552036199095" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.06540379149227324" LOG_CI_START="-0.13919626303606888" LOG_EFFECT_SIZE="-0.0368962357718978" ORDER="8335" O_E="0.0" SE="0.12018308481655209" STUDY_ID="STD-Regnier-1989" TOTAL_1="39" TOTAL_2="42" VAR="0.014443973876022552" WEIGHT="17.41560448046261"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.669695095401163" CI_START="0.30230994379917375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.4094207101528922" LOG_CI_START="-0.5195475674563698" LOG_EFFECT_SIZE="0.44493657134826115" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.36590415863014547" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="98" WEIGHT="99.99999999999999" Z="0.9041721062703504">
<NAME>Relapse after interval</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8336" O_E="0.0" SE="0.0" STUDY_ID="STD-Fischbach-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8337" O_E="0.0" SE="0.0" STUDY_ID="STD-Francois-1997" TOTAL_1="53" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="25.669695095401163" CI_START="0.30230994379917375" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4094207101528922" LOG_CI_START="-0.5195475674563698" LOG_EFFECT_SIZE="0.44493657134826115" ORDER="8338" O_E="0.0" SE="1.1330855148146515" STUDY_ID="STD-Regnier-1989" TOTAL_1="42" TOTAL_2="39" VAR="1.283882783882784" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.618164344775599" CI_END="1.904398777887331" CI_START="0.30325523474589267" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7599466418361317" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.27975789410211666" LOG_CI_START="-0.5181916936711717" LOG_EFFECT_SIZE="-0.11921689978452749" METHOD="MH" MODIFIED="2008-06-11 16:51:06 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.44526675488713396" P_Q="1.0" P_Z="0.5581086515201266" Q="0.0" RANDOM="YES" SCALE="128.6786646823487" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="116" WEIGHT="99.99999999999999" Z="0.5856531126940868">
<NAME>Reinfection after interval</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8339" O_E="0.0" SE="0.0" STUDY_ID="STD-Fischbach-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="94.1016504621935" CI_START="0.2277693366935764" EFFECT_SIZE="4.62962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9735972406465692" LOG_CI_START="-0.6425047429484307" LOG_EFFECT_SIZE="0.6655462488490691" ORDER="8340" O_E="0.0" SE="1.5367112550773752" STUDY_ID="STD-Francois-1997" TOTAL_1="53" TOTAL_2="49" VAR="2.3614814814814813" WEIGHT="9.303397329694478"/>
<DICH_DATA CI_END="1.9175989426036655" CI_START="0.22941234297323554" EFFECT_SIZE="0.6632653061224489" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.28275778154837594" LOG_CI_START="-0.6393832196476545" LOG_EFFECT_SIZE="-0.1783127190496393" ORDER="8341" O_E="0.0" SE="0.5416701887741223" STUDY_ID="STD-Regnier-1989" TOTAL_1="42" TOTAL_2="39" VAR="0.29340659340659336" WEIGHT="74.87834630387032"/>
<DICH_DATA CI_END="5.036404963596798" CI_START="0.04963858184697284" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7021206432754832" LOG_CI_START="-1.3041806346034457" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8342" O_E="0.0" SE="1.1785113019775793" STUDY_ID="STD-Vilaichone-2001" TOTAL_1="18" TOTAL_2="18" VAR="1.3888888888888888" WEIGHT="15.818256366435197"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Renal scarring (DMSA scan) after 6 months</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.49997449294851" CI_START="0.560194711128746" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.17608387394508243" LOG_CI_START="-0.251660995723882" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="8343" O_E="0.0" SE="0.2512594538148031" STUDY_ID="STD-Vilaichone-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.06313131313131315" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.438729437070475" CI_END="3.828542115494977" CI_START="0.1879860839829943" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8483587918185733" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="44.84005805561962" I2_Q="72.83952784851024" ID="CMP-001.11" LOG_CI_END="0.5830334288692857" LOG_CI_START="-0.7258742989974174" LOG_EFFECT_SIZE="-0.07142043506406583" METHOD="MH" MODIFIED="2008-06-11 17:15:30 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.1423496327777688" P_Q="0.05500895710447684" P_Z="0.8306324294286047" Q="3.681821120127876" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.0653257684395432" TOTALS="YES" TOTAL_1="150" TOTAL_2="142" WEIGHT="100.0" Z="0.21389052490949328">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5947307301105214" CI_END="1.5263124520975775" CI_START="0.29508107819930385" DF="2" EFFECT_SIZE="0.6711079823947682" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.18364344733555388" LOG_CI_START="-0.5300586383383952" LOG_EFFECT_SIZE="-0.17320759550142062" MODIFIED="2008-06-11 17:15:21 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.450514518397639" P_Z="0.34144038336351124" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="95" WEIGHT="81.40314413549277" Z="0.9513231244406261">
<NAME>Pediatric studies</NAME>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="8344" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Fischbach-1989" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="18.65265351978501"/>
<DICH_DATA CI_END="2.019020304420522" CI_START="0.33887449326308905" EFFECT_SIZE="0.8271604938271605" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.30514068647878084" LOG_CI_START="-0.4699611188344274" LOG_EFFECT_SIZE="-0.0824102161778233" ORDER="8345" O_E="0.0" SE="0.4552986372567942" STUDY_ID="STD-Francois-1997" TOTAL_1="72" TOTAL_2="67" VAR="0.20729684908789386" WEIGHT="46.45084622718225"/>
<DICH_DATA CI_END="7.676698731922972" CI_START="0.014473814199463616" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8851744972786274" LOG_CI_START="-1.8394170067179525" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8346" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Vilaichone-2001" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="16.299644388525508"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="211.3748518787445" CI_START="0.7082319434631973" DF="0" EFFECT_SIZE="12.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="2.3250533162733724" LOG_CI_START="-0.14982448910439747" LOG_EFFECT_SIZE="1.0876144135844876" MODIFIED="2008-06-11 17:15:30 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.08495023553356305" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="47" WEIGHT="18.596855864507233" Z="1.7226588521342066">
<NAME>Adult studies</NAME>
<DICH_DATA CI_END="211.3748518787445" CI_START="0.7082319434631973" EFFECT_SIZE="12.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3250533162733724" LOG_CI_START="-0.14982448910439747" LOG_EFFECT_SIZE="1.0876144135844876" ORDER="8347" O_E="0.0" SE="1.4537554737216178" STUDY_ID="STD-Regnier-1989" TOTAL_1="50" TOTAL_2="47" VAR="2.1134049773755654" WEIGHT="18.596855864507233"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-06-11 16:52:24 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Oral versus switch therapy</NAME>
<DICH_OUTCOME CHI2="3.45935111464823" CI_END="1.023359965113675" CI_START="0.9827167370045721" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.002832471401691" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="300" I2="42.18568934702156" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.010028422925030162" LOG_CI_START="-0.007571647258416242" LOG_EFFECT_SIZE="0.0012283878333069183" METHOD="MH" NO="1" P_CHI2="0.177342243673425" P_Q="1.0" P_Z="0.7844002168601935" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3913488579884065E-4" TOTALS="YES" TOTAL_1="294" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.27358935359170045">
<NAME>Clinical and bacteriological cure under therapy</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0128293490165874" CI_START="0.9873331583163105" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="153" LOG_CI_END="0.005536277518538242" LOG_CI_START="-0.005536277518538242" LOG_EFFECT_SIZE="0.0" ORDER="8348" O_E="0.0" SE="0.006504073638810129" STUDY_ID="STD-Hoberman-1999" TOTAL_1="153" TOTAL_2="153" VAR="4.230297389906483E-5" WEIGHT="58.90824564770131"/>
<DICH_DATA CI_END="1.1248873047187318" CI_START="0.9679608582475993" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="67" LOG_CI_END="0.051109015433737" LOG_CI_START="-0.014142204045710744" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="8349" O_E="0.0" SE="0.03832888932097331" STUDY_ID="STD-Mombelli-1999" TOTAL_1="69" TOTAL_2="72" VAR="0.0014691037565794218" WEIGHT="6.645895532687671"/>
<DICH_DATA CI_END="1.0259730036392085" CI_START="0.9746845155310323" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="80" LOG_CI_END="0.011135933363737862" LOG_CI_START="-0.011135933363737865" LOG_EFFECT_SIZE="0.0" ORDER="8350" O_E="0.0" SE="0.013082604763237598" STUDY_ID="STD-Neuhaus-2008" TOTAL_1="72" TOTAL_2="80" VAR="1.7115454739108707E-4" WEIGHT="34.44585881961103"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Clinical and bacteriological cure at end of treatment</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.128459746032535" CI_START="0.7780764937141091" EFFECT_SIZE="0.9370314842578711" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" LOG_CI_END="0.052486071709972326" LOG_CI_START="-0.10897770485491981" LOG_EFFECT_SIZE="-0.02824581657247374" ORDER="8351" O_E="0.0" SE="0.0948446216128019" STUDY_ID="STD-Gok-2001" TOTAL_1="29" TOTAL_2="25" VAR="0.008995502248875568" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection at end of treatment</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.6444505569118135" CI_START="0.1760231150665708" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8833462760561878" LOG_CI_START="-0.7544302976023509" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="8352" O_E="0.0" SE="0.9620380664918152" STUDY_ID="STD-Gok-2001" TOTAL_1="25" TOTAL_2="29" VAR="0.9255172413793104" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Relapse at end of treatment</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.591769983919673" CI_START="0.01159780173142795" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6619801247696183" LOG_CI_START="-1.935624319943967" LOG_EFFECT_SIZE="-0.6368220975871743" ORDER="8353" O_E="0.0" SE="1.525845709174138" STUDY_ID="STD-Gok-2001" TOTAL_1="25" TOTAL_2="29" VAR="2.3282051282051284" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03485423684076917" CI_END="1.0135722076418157" CI_START="0.9252097341371113" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9683836392468892" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="230" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.005854693594723033" LOG_CI_START="-0.033759806662556596" LOG_EFFECT_SIZE="-0.013952556533916775" METHOD="MH" NO="5" P_CHI2="0.9827238593120633" P_Q="1.0" P_Z="0.1673923729580525" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="245" WEIGHT="100.0" Z="1.380631239628509">
<NAME>Clinical and bacteriological cure rate after interval</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2988410275889413" CI_START="0.7566999471861726" EFFECT_SIZE="0.9913793103448276" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.1135559985973755" LOG_CI_START="-0.12107629634398906" LOG_EFFECT_SIZE="-0.003760148873306777" ORDER="8354" O_E="0.0" SE="0.1378241714971491" STUDY_ID="STD-Gok-2001" TOTAL_1="29" TOTAL_2="25" VAR="0.018995502248875563" WEIGHT="2.850577062928948"/>
<DICH_DATA CI_END="1.0315280295364295" CI_START="0.9061541894949986" EFFECT_SIZE="0.9668109668109668" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="132" LOG_CI_END="0.013481033479903986" LOG_CI_START="-0.04279789730186466" LOG_EFFECT_SIZE="-0.014658431910980322" ORDER="8355" O_E="0.0" SE="0.03305852252641123" STUDY_ID="STD-Hoberman-1999" TOTAL_1="147" TOTAL_2="140" VAR="0.0010928659116292384" WEIGHT="49.546922850522606"/>
<DICH_DATA CI_END="1.0348567135543638" CI_START="0.9066995072046894" EFFECT_SIZE="0.9686609686609686" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" LOG_CI_END="0.01488022146389501" LOG_CI_START="-0.04253662031103294" LOG_EFFECT_SIZE="-0.013828199423568974" ORDER="8356" O_E="0.0" SE="0.03372693707654325" STUDY_ID="STD-Neuhaus-2008" TOTAL_1="72" TOTAL_2="80" VAR="0.0011375062845651075" WEIGHT="47.602500086548446"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.012739952335595661" CI_END="1.1893185205937324" CI_START="0.3561876246943839" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6508613822123113" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.07529818196161037" LOG_CI_START="-0.4483211736439868" LOG_EFFECT_SIZE="-0.1865114958411882" METHOD="MH" MODIFIED="2008-06-11 16:51:55 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.9936502691885017" P_Q="0.9408351065939746" P_Z="0.16263456589499184" Q="0.005508650476020114" RANDOM="YES" SCALE="41.09916474674097" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="305" TOTAL_2="323" WEIGHT="200.0" Z="1.3962654765832094">
<NAME>Reinfection after interval</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.674868828188838" CI_START="0.26656830351995914" DF="0" EFFECT_SIZE="0.6681818181818182" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.22398079977615992" LOG_CI_START="-0.57419149192422" LOG_EFFECT_SIZE="-0.1751053460740301" NO="1" P_CHI2="1.0" P_Z="0.3898082697820463" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="147" WEIGHT="100.0" Z="0.8599651362850179">
<NAME>Symptomatic superinfection</NAME>
<DICH_DATA CI_END="1.674868828188838" CI_START="0.2665683035199591" EFFECT_SIZE="0.6681818181818182" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.22398079977615992" LOG_CI_START="-0.5741914919242201" LOG_EFFECT_SIZE="-0.1751053460740301" ORDER="8357" O_E="0.0" SE="0.46885035516136836" STUDY_ID="STD-Hoberman-1999" TOTAL_1="140" TOTAL_2="147" VAR="0.21982065553494123" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.007232102448636527" CI_END="1.4182664195261871" CI_START="0.2870676046880143" DF="1" EFFECT_SIZE="0.6380739329128161" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.15175782017140604" LOG_CI_START="-0.5420158144663912" LOG_EFFECT_SIZE="-0.19512899714749254" NO="2" P_CHI2="0.9322281844708359" P_Z="0.2702405046408065" STUDIES="2" TAU2="0.0" TOTAL_1="165" TOTAL_2="176" WEIGHT="100.0" Z="1.1025089096911858">
<NAME>Symptomatic and asymptomatic superinfection</NAME>
<DICH_DATA CI_END="6.02171648023104" CI_START="0.05586447005673255" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="8358" O_E="0.0" SE="1.1939502675485736" STUDY_ID="STD-Gok-2001" TOTAL_1="25" TOTAL_2="29" VAR="1.4255172413793102" WEIGHT="11.650332289493651"/>
<DICH_DATA CI_END="1.5114230484380642" CI_START="0.2762395302432874" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.17938604070373967" LOG_CI_START="-0.5587141731936499" LOG_EFFECT_SIZE="-0.18966406624495508" ORDER="8359" O_E="0.0" SE="0.4335637192983108" STUDY_ID="STD-Hoberman-1999" TOTAL_1="140" TOTAL_2="147" VAR="0.1879774986917844" WEIGHT="88.34966771050635"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Relapse after interval</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="114.79424959799184" CI_START="0.2899450432856988" EFFECT_SIZE="5.769230769230769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.059920133441656" LOG_CI_START="-0.5376843112719294" LOG_EFFECT_SIZE="0.7611179110848633" ORDER="8360" O_E="0.0" SE="1.525845709174138" STUDY_ID="STD-Gok-2001" TOTAL_1="25" TOTAL_2="29" VAR="2.3282051282051284" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.512174795411277" CI_END="2.160658718440343" CI_START="0.3481187043357433" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8672748777493673" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="44" I2="77.8377380012635" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.3345861743783265" LOG_CI_START="-0.4582726415488959" LOG_EFFECT_SIZE="-0.06184323358528468" METHOD="MH" MODIFIED="2008-06-11 16:52:12 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.033654472177651606" P_Q="1.0" P_Z="0.7597907387989402" Q="0.0" RANDOM="YES" SCALE="5.768830796984472" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3413664120684284" TOTALS="YES" TOTAL_1="212" TOTAL_2="212" WEIGHT="100.0" Z="0.30575559754079085">
<NAME>Renal scarring (DMSA scan) after 6 months</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.033727868273327" CI_START="0.6894912127520703" EFFECT_SIZE="1.4462809917355373" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.4819766210756883" LOG_CI_START="-0.1614712643359996" LOG_EFFECT_SIZE="0.1602526783698444" ORDER="8361" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Hoberman-1999" TOTAL_1="132" TOTAL_2="140" VAR="0.14285714285714288" WEIGHT="44.794120232921834"/>
<DICH_DATA CI_END="0.89367265301748" CI_START="0.36704326558284406" EFFECT_SIZE="0.5727272727272728" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" LOG_CI_END="-0.04882153156436513" LOG_CI_START="-0.43528273984492166" LOG_EFFECT_SIZE="-0.24205213570464332" ORDER="8362" O_E="0.0" SE="0.22700922675783256" STUDY_ID="STD-Neuhaus-2008" TOTAL_1="80" TOTAL_2="72" VAR="0.051533189033189035" WEIGHT="55.20587976707817"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.4200334863321227" CI_END="3.7374060438798757" CI_START="-2.943218537882088" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39709375299889377" ESTIMABLE="YES" I2="17.356515465773096" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2008-06-11 16:52:24 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.29819235428226565" P_Q="1.0" P_Z="0.81576217529176" Q="0.0" RANDOM="YES" SCALE="15.404019975367234" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.600923430496541" TOTALS="YES" TOTAL_1="410" TOTAL_2="424" UNITS="" WEIGHT="99.99999999999997" Z="0.23299900925084105">
<NAME>Mean time to cessation of fever (hours)</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.010043327016814" CI_START="-4.410043327016813" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="23.9" ORDER="8363" SD_1="23.2" SD_2="23.3" SE="2.6582342166044732" STUDY_ID="STD-Hoberman-1999" TOTAL_1="153" TOTAL_2="153" WEIGHT="33.51216773449209"/>
<CONT_DATA CI_END="2.752282857667911" CI_START="-12.35228285766792" EFFECT_SIZE="-4.800000000000004" ESTIMABLE="YES" MEAN_1="40.8" MEAN_2="45.6" ORDER="8364" SD_1="20.43" SD_2="24.99" SE="3.853276344483551" STUDY_ID="STD-Mombelli-1999" TOTAL_1="72" TOTAL_2="69" WEIGHT="17.658238738047064"/>
<CONT_DATA CI_END="6.086608945569957" CI_START="-2.0866089455699566" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="36.9" MEAN_2="34.9" ORDER="8365" SD_1="20.2" SD_2="20.8" SE="2.0850428772184624" STUDY_ID="STD-Montini-2007" TOTAL_1="185" TOTAL_2="202" WEIGHT="48.82959352746083"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.021922711114962" CI_START="0.06113749853727023" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="1.1767255231732376" LOG_CI_START="-1.213692334561264" LOG_EFFECT_SIZE="-0.018483405694013126" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.975819803481315" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="259" WEIGHT="100.0" Z="0.030310022454602938">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.021922711114962" CI_START="0.06113749853727023" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1767255231732376" LOG_CI_START="-1.213692334561264" LOG_EFFECT_SIZE="-0.018483405694013126" ORDER="8366" O_E="0.0" SE="1.4041432823924782" STUDY_ID="STD-Mombelli-1999" TOTAL_1="72" TOTAL_2="69" VAR="1.9716183574879227" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8367" O_E="0.0" SE="0.0" STUDY_ID="STD-Neuhaus-2008" TOTAL_1="175" TOTAL_2="190" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-06-11 16:53:01 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Oral versus parenteral therapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological cure at end of treatment</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.844714621847888" CI_START="1.0232449440032454" EFFECT_SIZE="1.3738977072310405" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.2659291901466418" LOG_CI_START="0.009979607412673987" LOG_EFFECT_SIZE="0.13795439877965787" ORDER="8368" O_E="0.0" SE="0.15034605186880062" STUDY_ID="STD-Puppo-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.022603935312536086" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-11 16:53:01 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.348705906050781" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological cure after interval</NAME>
<GROUP_LABEL_1>Parenteral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0760010392702855" CI_START="1.2392035420521896" EFFECT_SIZE="1.9523809523809523" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.4879864778619272" LOG_CI_START="0.09314264610970518" LOG_EFFECT_SIZE="0.2905645619858162" ORDER="8369" O_E="0.0" SE="0.2319332212797443" STUDY_ID="STD-Puppo-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.05379301913319884" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-06-11 16:53:39 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Single shot/oral versus switch therapy</NAME>
<DICH_OUTCOME CHI2="1.44431569868178" CI_END="1.019293423985485" CI_START="0.8563804319828414" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9342927500253649" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="107" I2="30.76305956428396" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.008299222351872533" LOG_CI_START="-0.06733326475331684" LOG_EFFECT_SIZE="-0.029517021200722176" METHOD="MH" NO="1" P_CHI2="0.22944251818680816" P_Q="1.0" P_Z="0.12605963469656986" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0012549833717086583" TOTALS="YES" TOTAL_1="114" TOTAL_2="111" WEIGHT="100.0" Z="1.5298266842358341">
<NAME>Clinical cure under therapy</NAME>
<GROUP_LABEL_1>IV switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9852836618507735" CI_START="0.8236087918020757" EFFECT_SIZE="0.9008264462809917" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="60" LOG_CI_END="-0.006438718699040646" LOG_CI_START="-0.08427902605261224" LOG_EFFECT_SIZE="-0.04535887237582645" ORDER="8370" O_E="0.0" SE="0.04572378185522366" STUDY_ID="STD-Millar-1995" TOTAL_1="60" TOTAL_2="60" VAR="0.0020906642271440803" WEIGHT="58.99453383813296"/>
<DICH_DATA CI_END="1.1067531620609716" CI_START="0.8759887027143926" EFFECT_SIZE="0.9846335697399528" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="47" LOG_CI_END="0.04405077145835757" LOG_CI_START="-0.05750149472282943" LOG_EFFECT_SIZE="-0.006725361632235929" ORDER="8371" O_E="0.0" SE="0.059652303846654174" STUDY_ID="STD-Sanchez-2002" TOTAL_1="54" TOTAL_2="51" VAR="0.003558397354213552" WEIGHT="41.005466161867034"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="54" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Bacterial cure under therapy</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0375385039113114" CI_START="0.9638196522155094" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="51" LOG_CI_END="0.01600422271032416" LOG_CI_START="-0.01600422271032413" LOG_EFFECT_SIZE="0.0" ORDER="8372" O_E="0.0" SE="0.01880191928444901" STUDY_ID="STD-Sanchez-2002" TOTAL_1="54" TOTAL_2="51" VAR="3.5351216877893554E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2008-06-11 16:53:32 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.5531031999439033" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="51" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean time to cessation of fever (days)</NAME>
<GROUP_LABEL_1>Single shot therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3882086465654635" CI_START="-0.18820864656546377" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.6" ORDER="8373" SD_1="0.8" SD_2="0.7" SE="0.14704792987974097" STUDY_ID="STD-Sanchez-2002" TOTAL_1="51" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2008-06-11 16:53:39 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0271568559445208" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="51" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean time of clinical symptoms (days)</NAME>
<GROUP_LABEL_1>Single shot therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7597433273593883" CI_START="-0.15974332735938868" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.0" ORDER="8374" SD_1="1.1" SD_2="1.3" SE="0.23456723235007643" STUDY_ID="STD-Sanchez-2002" TOTAL_1="51" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="54" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Clinical cure at end of therapy</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0375385039113114" CI_START="0.9638196522155094" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="51" LOG_CI_END="0.01600422271032416" LOG_CI_START="-0.01600422271032413" LOG_EFFECT_SIZE="0.0" ORDER="8375" O_E="0.0" SE="0.01880191928444901" STUDY_ID="STD-Sanchez-2002" TOTAL_1="54" TOTAL_2="51" VAR="3.5351216877893554E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Bacterial cure at end of therapy</NAME>
<GROUP_LABEL_1>Switch therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1628792441461457" CI_START="0.7901606594492739" EFFECT_SIZE="0.9585726004922067" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.06553461900719329" LOG_CI_START="-0.10228459678746575" LOG_EFFECT_SIZE="-0.01837498889013623" ORDER="8376" O_E="0.0" SE="0.09857783807629858" STUDY_ID="STD-Millar-1995" TOTAL_1="53" TOTAL_2="57" VAR="0.009717590159796941" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="34.750218874646706" CI_START="0.46042875464227334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="1.5409575443434547" LOG_CI_START="-0.3368375616875297" LOG_EFFECT_SIZE="0.6020599913279625" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.20882244328904864" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="114" WEIGHT="100.0" Z="1.2568100702205507">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Single shot therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Switch therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours switch</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.750218874646706" CI_START="0.46042875464227323" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5409575443434547" LOG_CI_START="-0.3368375616875298" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="8377" O_E="0.0" SE="1.1030261405182866" STUDY_ID="STD-Millar-1995" TOTAL_1="60" TOTAL_2="60" VAR="1.2166666666666668" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8378" O_E="0.0" SE="0.0" STUDY_ID="STD-Sanchez-2002" TOTAL_1="51" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Single shot/oral versus oral therapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Clinical and bacteriological cure under therapy</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1660850345893272" CI_START="0.8092664268863539" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.06673022169774243" LOG_CI_START="-0.0919084763137834" LOG_EFFECT_SIZE="-0.012589127308020516" ORDER="8379" O_E="0.0" SE="0.09318515648619015" STUDY_ID="STD-Baker-2001" TOTAL_1="35" TOTAL_2="34" VAR="0.008683473389355746" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological cure under therapy</NAME>
<GROUP_LABEL_1>Oral therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Single shot therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1381790326642807" CI_START="0.8291081124370903" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.05621058084876274" LOG_CI_START="-0.08138883546480379" LOG_EFFECT_SIZE="-0.012589127308020516" ORDER="8380" O_E="0.0" SE="0.08082657827068485" STUDY_ID="STD-Baker-2001" TOTAL_1="35" TOTAL_2="34" VAR="0.006532935754947143" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection or relapse after interval</NAME>
<GROUP_LABEL_1>Single shot therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8381" O_E="0.0" SE="0.0" STUDY_ID="STD-Baker-2001" TOTAL_1="34" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Single shot therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single shot</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.681821804525148" CI_START="0.33156457137146966" EFFECT_SIZE="1.3725490196078431" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7544876090903714" LOG_CI_START="-0.47943188125773056" LOG_EFFECT_SIZE="0.13752786391632046" ORDER="8382" O_E="0.0" SE="0.7248104166304609" STUDY_ID="STD-Baker-2001" TOTAL_1="34" TOTAL_2="35" VAR="0.5253501400560223" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-06-11 16:34:14 +1000" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2008-06-11 16:34:14 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2008-06-11 16:31:42 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-11 16:34:14 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1 MeSH descriptor Urinary Tract Infections explode all trees<BR/>#2 MeSH descriptor Bacteriuria explode all trees<BR/>#3 MeSH descriptor Pyuria explode all trees<BR/>#4 MeSH descriptor Pyelonephritis explode all trees<BR/>#5 MeSH descriptor Cystitis explode all trees<BR/>#6 MeSH descriptor Urethritis explode all trees<BR/>#7 uti in Clinical Trials<BR/>#8 pyelonephritis in Clinical Trials<BR/>#9 bacteriuria or pyuria in Clinical Trials<BR/>#10 (urin* or kidney* or renal) and (infect* or inflam*) in Clinical Trials<BR/>#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 MeSH descriptor Anti-Bacterial Agents explode all trees<BR/>#13 MeSH descriptor Anti-Infective Agents, Urinary explode all trees<BR/>#14 antibiotic* in Clinical Trials<BR/>#15 (#12 OR #13 OR #14)<BR/>#16 MeSH descriptor Administration, Oral explode all trees<BR/>#17 oral* or (per next os) or po in Clinical Trials<BR/>#18 MeSH descriptor Injections explode all trees<BR/>#19 MeSH descriptor Infusions, Parenteral explode all trees<BR/>#20 MeSH descriptor Infusions, Intravenous explode all trees<BR/>#21 intra-venous* or intravenous* or iv or parenteral* or intramuscular* or intra-muscular* or im or (intra next muscular*) in Clinical Trials<BR/>#22 (#16 OR #17 OR #18 OR #19 OR #20 OR #21)<BR/>#23 (#11 AND #15 AND #22)</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>1. urinary tract infections/ or bacteriuria/ or pyuria/ or pyelonephritis/<BR/>2. ((urin$ or kidney$ or renal) and (infect$ or inflam$)).tw.<BR/>3. exp Cystitis/<BR/>4. exp Urethritis/<BR/>5. uti.tw.<BR/>6. pyelonephritis.tw.<BR/>7. (bacteriuria or pyuria).tw.<BR/>8. or/1-7<BR/>9. exp Anti-Bacterial Agents/<BR/>10. exp Anti-Infective Agents, Urinary/<BR/>11. antibiotic$.tw.<BR/>12. or/9-11<BR/>13. exp Injections/<BR/>14. exp Infusions Parenteral/<BR/>15. (intra-venous$ or intravenous$ or iv or parenteral$).tw.<BR/>16. or/13-15<BR/>17. exp Administration Oral/<BR/>18. (oral$ or per os or po).tw.<BR/>19. or/17-18<BR/>20. or/16,19<BR/>21. and/16,19<BR/>22. and/8,12,20<BR/>23. and/8,12,21</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>1. urinary tract infections/ or bacteriuria/ or pyuria/ or pyelonephritis/<BR/>2. ((urin$ or kidney$ or renal) and (infect$ or inflam$)).tw.<BR/>3. exp Cystitis/<BR/>4. exp Urethritis/<BR/>5. uti.tw.<BR/>6. pyelonephritis.tw.<BR/>7. (bacteriuria or pyuria).tw.<BR/>8. or/1-7<BR/>9. exp Anti-Bacterial Agents/<BR/>10. exp Anti-Infective Agents, Urinary/<BR/>11. antibiotic$.tw.<BR/>12. or/9-11<BR/>13. exp Injections/<BR/>14. exp Infusions Parenteral/<BR/>15. (intra-venous$ or intravenous$ or iv or parenteral$).tw.<BR/>16. or/13-15<BR/>17. exp Administration Oral/<BR/>18. (oral$ or per os or po).tw.<BR/>19. or/17-18<BR/>20. or/16,19<BR/>21. and/16,19<BR/>22. and/8,12,20<BR/>23. and/8,12,21</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>